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Zusammenfassung  
Parasiten können ihrer Eliminierung entgehen und aus 
der Manipulation des wirtseigenen Immunsystems Nutzen 
für ihr eigenes Überleben ziehen. Sie sind in der Lage, 
regulatorische T-Zell (Treg)-Populationen zu induzieren, 
welche Ausmaß und Ausprägung von Effektor-T-Zell-
Funktionen modulieren können. Dies kann zu ineffizienten 
Immunantworten bei Infektionen beitragen. 
Nukleotidveränderungen in der Promoter Region von 
Genen die Immunantworten regulieren, können nicht nur 
zu einer veränderten Genexpression führen, sondern dies 
kann sich auch in einer veränderten Empfänglichkeit für 
parasitäre Infektionen und in Veränderungen der immun 
regulatorisch wirkenden T-Zellen (Treg) widerspiegeln. In 
der vorliegenden Arbeit konnten zwei bekannte 
Einzelnukleotid-Polymorphismen (Single Nucleotide 
Polymorphism, SNP) (rs2069762T/G und rs2067006T/G) 
sowie eine bis dahin unbekannte CT Deletion 
(#ss410961576) an der Position -83/-84 der IL2 Promoter 
Region bei allen 40 untersuchten, nicht miteinander 
verwandten gabunesischen Individuen identifiziert werden. 
Keines der untersuchten SNP Konstrukte wies im 
Vergleich zum Hauptallel (rs2067006T/A) eine veränderte 
Luciferase Aktivität in vitro auf, was möglicherweise mit 
der auf Tregs beschränkten Expression von FOXP3 
zusammenhängt, welche zu einer leichte Veränderung 
der Effektor-T-Zell-Funktion führen könnte.  Im Bezug auf 
IL-2R alpha (CD25) konnten zwei bereits bekannte 
Varianten (rs12722617C/T und rs12722616C/T) sowie 
eine bis dahin unbekannte C/T Variante (#ss410961577) 
an Position -409 der Promoter Region beschrieben 
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werden. Die SNP's rs12722617C/T und rs12722616C/T 
konnten bei allen untersuchten Individuen nachgewiesen 
werden und zeigten nach Stimulation keine Unterschiede 
zum Hauptallel. Die neu identifizierte Variante 
#ss410961577 hingegen wies im Vergleich zum 
Hauptallel eine signifikant reduzierte Aktivität auf. Ein 
Vergleich mit der NCBI HapMap Datenbank ergab 
übereinstimmende Verteilungen der untersuchten SNP 
Varianten für IL2 und IL2R alpha mit denen der Yoruba 
Population, welche eine ethnische Gruppe aus 
Subsahara Afrika darstellt. Die identifizierten 
regulatorischer SNP's könnten für weiterführende 
Untersuchungen zur Krankheitsanfälligkeit oder zur 
besseren Charakterisierung unterschiedlicher 
physiologischer Antworten verwendet werden.  
Unterschiedliche Ausprägungen von wirtseigenen 
Immunantworten können zur Beseitigung einer Infektion 
beitragen, aber auch die Persistenz von Parasiten im Wirt 
und somit einen chronischen Infektionsverlauf fördern. In 
der vorliegenden Arbeit wurden Immunreaktivität und 
regulatorische Immunprozesse im Rahmen der 
Alveolären Echinokokkose (AE) untersucht. Klar 
unterscheidbare zelluläre und humorale 
Immunantwortprofile konnten hierbei bei Patienten mit 
unterschiedlichen Verlaufsformen der AE beobachtet 
werden. AE Patienten mit stabiler und progressiver 
Verlaufsform wiesen erhöhte Plasmakonzentrationen von 
IL-17B und seinem löslichen Rezeptor IL-17RB auf, 
während die Plasmakonzentrationen von IL-17F, IL-31, 
IL-33, Eotaxin-2/CCL24 sowie des regulatorischen IL-27 
bei allen AE Patienten deutlich reduziert waren. Diese 
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Beobachtungen decken sich mit einer verminderten 
Produktion von IL-17F und IL-27 durch Periphere 
Mononukleäre Blutzellen (Peripheral Blood Mononuclear 
Cells, PBMC) von AE Patienten nach Stimulation mit 
Echinococcus multilocularis Metacestoden  (Em) 
Antigenen. Im Gegensatz hierzu konnte nach Stimulation 
mit Em Antigenen eine erhöhte Produktion von IL-31 und 
CCL24 durch PBMC beobachten werden. Darüber hinaus 
war die Spontanproduktion von IL-31 und IL-33 durch 
PBMC bei allen AE Patienten reduziert, während 
regulatorisches IL-27, anti-inflammatorisches SDF-
1/CXCL12 und Eosinophile Granulozyten aktivierendes 
Eotaxin-1, -2 und -3 (CCL11, CCL24, CCL26) mit 
progressivem Krankheitsverlauf zunahmen.  
Antikörper Antworten gegen Em Antigen und 
Echinococcus multilocularis  Vesikel (EmV) Antigen 
nahmen mit zunehmender Schwere der Erkrankung zu, 
wobei die höchste Reaktivität bei Patienten mit 
progressiver AE beobachtet werden konnte. Die geringste 
IgG Subklassen Reaktivität war bei Patienten mit 
ausgeheilter AE und bei Kontrollen nachweisbar. 
Weiterhin konnte, mit Ausnahme von IgG4, eine klar 
unterscheidbare Antikörper Reaktivität gegen EmV 
Antigen bei ausgeheilter, stabiler und progressiver AE 
beobachtet werden.  
Die Resultate dieser Arbeit zeigen die Entwicklung eines 
ausgewogenen Reaktionsprofils von pro-
inflammatorischen und regulatorischen Cytokinen und 
Chemokinen bei Patienten mit Alveolären Echinokokkose. 
Die Kenntnis dieser Reaktionsprofile hilft nicht nur einen 
schweren Krankeitsverlauf zu erkennen, sondern trägt 
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auch zur Identifizierung von regulatorischen 
Komponenten bei, die den Wirt gegen Schäden durch 
Effektorzellen des Immunsystems schützen können. Ein 
umfassendes Verständnis der Immunantworten bei einem 
progressiven oder ausheilenden Verlauf der Alveolären 
Echinokokkose, kann die Betreuung von AE Patienten 
verbessern und neue Interventionsmöglichkeiten im Sinne 
einer Immuntherapie eröffnen. 
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Summary 
Parasites may escape their elimination and benefit for 
their survival in the host by manipulating the host immune 
response system. Parasites induce regulatory T cell 
(Tregs) populations that modulate the magnitude and 
expression of effector T cell functions thereby leading to 
an ineffective immune response during infections. Any 
nucleotide alteration in the promoter region may modify 
the gene expression, reflecting the level of susceptibility 
to a parasitic infection as well as Tregs expression. In this 
work, two known SNPs (rs2069762T/G and 
rs2067006T/A) and one novel CT deletion 
(#ss410961576) at the position -83/-84 were identified in 
the IL2 promoter region in all the forty unrelated 
Gabonese individuals. None of the investigated SNP 
constructs showed a differential luciferase activity in vitro 
compared with the major allele (rs2067006T/A), which 
may relate to restricted FOXP3 expression in the Tregs 
leading to a slight alteration in T effector cell function. For 
the IL2R alpha (CD25), two previously described variants 
(rs12722617C/T and rs12722616C/T) and one novel C/T 
variant (#ss410961577) at position -409 were observed in 
the promoter region. The SNPs rs12722617C/T and 
rs12722616C/T were observed to be in absolute linkage 
in all individuals analyzed, and reveal no difference with 
the major allele after stimulation. The newly identified 
variant #ss410961577 showed a significantly decreased 
activity when compared to the major allele. When 
compared to the NCBI HapMap database, all the 
frequencies of the reported SNP variants in IL2 and IL2R 
alpha were found to be in accordance with the Yoruba 
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population which represents a Sub Saharan African group. 
The identified regulatory SNPs may be used for future 
prospective studies examining disease susceptibility or 
may better elucidate various physiological responses.  
The diverse expression of the host immune responses 
may either help to clear infection or else allow for parasite 
persistence and chronic disease courses. In the present 
works, immune reactions and immune regulatory 
processes were studied during the course of Alveolar 
Echinococcosis (AE). Distinct humoral and cellular 
immune response profiles were observed in patients with 
different infection stages of AE. Elevated plasma levels of 
pro-inflammatory IL-17B and its soluble receptor IL-17RB 
were observed in stable and progressive AE patients. 
While plasma levels of pro-inflammatory IL-17F, IL-31, IL-
33, Eotaxin-2/CCL24 and regulatory IL-27 were drastically 
depressed in all AE patients. These observations 
paralleled with reduced secretion of IL-17F and IL-27 by 
Peripheral Blood Mononuclear Cells (PBMC) from AE 
patients after stimulation with Echinococcus multilocularis 
antigens. In contrast, the expression of IL-31 and CCL24 
by PBMC were enhanced after E. multilocularis antigen 
stimulation. In addition, the spontaneous release of IL-31 
and IL-33 by PBMC was decreased in all AE patients, 
while regulatory IL-27, anti-inflammatory SDF-1/CXCL12 
as well as eosinophil granulocyte attracting Eotaxin-1, -2 
and -3 (CCL11, CCL24, CCL26) were enhanced with 
disease progression.  
Antibody responses to E. multilocularis metacestode 
antigen (EmAg) and E. multilocularis vesicle antigen 
(EmVAg) were increased with disease progression, the 
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highest reactivity being observed in patients with 
progressive AE. Lowest IgG subclass responses were 
present in cured AE patients and controls. Furthermore, 
antibody reactivity against EmVAg distinctly separated 
between cured, stable or progressive AE, with the 
exception of IgG4.  
These results reveal that equilibrated levels of pro-
inflammatory and regulatory cytokines and chemokines 
have evolved to prevent severe disease manifestation 
and progression. At the same time, regulatory 
components may protect the host against immune-
effecter cells mediated damage. Such distinctive 
response profiles could provide a better understanding of 
the immune response during disease progression or 
regression and improve the monitoring of AE patients.  
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Introduction 
 
Innate and adaptive immune responses 
 
Most pathogens which persist in their hosts can overcome 
the innate immune system, and an adaptive immune 
response is induced consequently for defense against 
them. The adaptive immune system consists of two major 
types of lymphocytes: B lymphocytes, which mature in the 
bone marrow and then differentiate into circulating plasma 
cells which secrete antibodies; and T lymphocytes, which 
mature in the thymus and may either kill pathogen-
infected cells or help to eliminate extracellular pathogens. 
T cells become activated after having had contact with 
peptides on antigen-presenting cells, these peptides 
being presented as ligands by the major histocompatibility 
(MHC) complex.  
Following maturation in the thymus, T lymphocytes will 
mainly develop into two classes: Cytotoxic T cells, which 
are CD8-positive, will detect and kill pathogen-infected 
cells when recognizing pathogen-specific peptide 
antigens presented on MHC class I molecule; The second 
T cell population are initially naïve CD4-positive T helper 
cells, which expand into effector T cells after their 
activation by pathogen-specific peptide antigens 
presented on MHC class II molecules. T helper cell may 
differentiate into Th1-, Th2- and Th17-type cells, as well 
as into regulatory T cells (Tregs) subsets which regulated 
immune responses.  
Activated CD8-positive cytotoxic T cells will eliminate 
infection by inducing their target to undergo apoptosis, 
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and cytotoxic T cells may kill single infected cells in a 
strict antigen-restricted manner without creating 
widespread inflammation. The cytokine interferon-gamma 
(IFN-gamma), which is produced by CD8-postive 
cytotoxic T cells, will inhibit intracellular viral replication 
directly, and IFN-gamma is essential for the induction of 
MHC class I molecule expression and macrophage 
activation. In the MHC class I lessened mice, where CD8 
T cell production is missing, the susceptibility to infection 
with the intracellular protozoan parasite Trypanosoma 
cruzi was increased (Munoz Fernandez et al. 1992). 
T helper cell subsets are defined by the differing cytokine 
and chemokine secretion profiles, as well as by the 
differential expression of surface receptors. Both Th1- 
and Th2-T cell subsets are involved and predominate in 
acute and chronic infections with extracellular pathogens, 
respectively. During the initial pathogen encounter and 
antigen contact, the cytokines and chemokines produced 
by innate immune response drive the differentiation of 
Th1 and Th2 cells. When IFN-gamma is produced, the 
transcription factor STAT-1 (signal-transducing activator 
of transcription 1) can promote naïve T cells to 
differentiate into the type-1 T helper subset. Interleukin-4 
(IL-4) will predominate upon the first antigen encounter, 
and is one of the most powerful trigger for the 
development of type-2 T helper cell, as well as the 
transcription factor STAT-4 and GATA-3. The 
development of Th17-type cells from naïve CD4 T cells 
will be promoted by IL-6 and transforming growth factor 
(TGF)-beta. 
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Th1-type cells can activate macrophages to control 
certain intracellular parasite infections by producing 
cytokines, such as IFN-gamma and TNF-alpha (Bogdan 
et al. 1990, Liew et al. 1990). Activated macrophages are 
tightly regulated by Th1 cells which help to minimize local 
tissue damage and energy consumption. Th1 cells can 
stimulate in humans the production of certain antibody 
subclasses, namely IgG1 and IgG3, which mainly act 
against bacterial pathogens and also by producing co-
stimulatory signals which interact with naïve B 
lymphocytes. Furthermore, Th1 cells are traditionally 
associated with delayed-type hypersensitivity reactions 
(Glimcher & Murphy 2000, Coffman 2006). 
T helper type-2 cells will also activate naïve B 
lymphocytes to produce certain antibody subclasses and 
will induce antibody subclass switching; this is related to 
the production of IgG2, IgG4 and IgE antibodies, those 
being involved in anti-helminth and anti-allergy type 
immune responses (Else & Finkelman 1998, Glimcher & 
Murphy 2000, Coffman 2006). Although initially in many 
infections mixed Th1- and Th2-type responses will evolve, 
such mixed type responses being mediated by 
“promiscuous” cytokines, but with long lasting parasite 
persistence and chronic infections a Th2- or a Th1-type 
immune response profile will predominate. 
Th17 cells are often the first effector T cells subset which 
will develop following infection; Th17 cells can induce 
local epithelial and stromal cells to produce chemokines 
that recruit neutrophils to the site of infection. Several 
studies showed that IL-17 play an important role in 
promoting protection against bacteria and protozoan 
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parasite infections (Happel et al 2003, Kelly et al. 2005, 
Rudner et al. 2007). In addition, elevated levels of Th17 
cytokines have been implicated in the induction of several 
autoimmune diseases (Bettelli et al. 2007).  
Regulatory T cells (Treg) restrain inflammation and 
maintain tolerance through the secretion of inhibitory 
cytokines, mainly IL-10 and TGF-beta. Several studies 
have shown that Treg cells can also control effector T cell 
responses (Shevach et al. 2006).  TGF-beta is a critical 
differentiation factor for the generation of Treg cells, but 
IL-6, an acute phase protein induced during inflammation, 
completely inhibits the generation of Treg cells induced by 
TGF-beta. Furthermore, IL-6 and TGF-beta together 
induce the differentiation of pathogenic Th17 cells from 
naive T cells. Thus, the generations of pathogenic Th17 
cells by IL-6 that induce autoimmunity, and of regulatory T 
cells by TGF-beta that inhibit autoimmune tissue injury 
are selectively and dichotomously inducible (Bettelli et al. 
2006).  
 
Cytokines and chemokines 
 
Cytokines are small immune modulating glycol proteins, 
which are secreted by a wide range of cells, including 
macrophages, B and T lymphocytes, as well as 
endothelial cells, fibroblasts, and stromal cells; cytokine 
modulate the proliferation and bioactivity of various cell 
types and many cytokines can be secreted by more than 
one cell type. The expression of cytokines can be 
regulated at the level of gene transcription and translation, 
at the protein synthesis levels and the cytokine synthesis 
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differs between cell types and their developmental stage 
and age.  
The differentiation into Th1 cells will occur in the presence 
of IL-12 and IFN-gamma through toll-like receptor (TLR) 
signaling pathways. Also important in the early stage of 
Th1 differentiation is IL-2 (Liao et al. 2011); if an IL-12 
production is inhibited, the secretion of IFN-gamma will 
lessen and the development of Th1 cells will dysfunction 
(Magram et al. 1996, O’Garra & Murphy 2009). IFN-
gamma is the hallmark cytokine for Th1 cells and vital in 
directing Th1 cell differentiation, in parallel, IFN-gamma 
will suppress the production of Th2- and Th17-type 
cytokines.  
The differentiation and evolution of Th2-type cells 
depends on the presence of IL-4 and the transcription 
factor GATA3 (Zhu et al. 2010). Th2-type cells will secrete 
IL-5, IL-6, and IL-13 (Paul & Zhu 2010), where IL-5 and 
IL-13 drive the differentiation, recruitment and survival of 
eosinophil granulocytes (Jabara et al. 1988, Horie et al. 
1997), and the recently discovered Th2-type cytokine IL-
33 can alter the Th2-type cell cytokine expression 
(Schmitz et al. 2005).  
Th17-type cells were generated in the presence of IL-6, 
IL-1 beta and TGF-beta those often being synthesized by 
dendritic cells, and furthermore, IL-23 may expand and 
maintain Th17 cell populations (Bettelli et al. 2006, Dong 
2006, Mangan et al. 2006). Th17 cells can produce IL-22, 
and together with IL-17, this population will induce an 
acute inflammatory response at the early stage of 
infection (Liang et al. 2006, Ma 2008). The IL-17 family 
contains six members, namely, IL-17A, IL-17B, IL-17C, 
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IL-17D, IL-17E and IL-17F. The cytokines IL-17A and IL-
17F are highly homologous and bind to the same receptor, 
and both contribute similarly to the progress of 
inflammation and to the host defense against pathogens 
(Iwakura et al. 2008, Reynolds et al. 2010). The cytokine 
IL-17E appears to be involved in promoting Th2 cell 
immune responses playing a pivotal role in protection 
against parasitic worms (Fallon et al. 2006, Owyang et al. 
2006).  
Regulatory T cells (Treg) are associated with the 
cytokines TGF-beta, IL-10 and IL-2 (Vignali 2008). While 
the TGF-beta and IL-2 combination is essential for 
conversion of CD4+CD25- non-Treg cells into Treg cells, 
and thus enhancing the suppressive effects of Treg cells 
(Levings et al. 2001, Taylor et al. 2002, Horwitz et al. 
2003). Furthermore, presence of other types of cells, in 
particular antigen-presenting cells (APCs), is critical for 
the generation of Tregs (Wan & Flavell 2006). Members 
of the TNF-nerve growth factor receptor family, notably 
TNFRSF18, is highly expressed on the surface of Treg 
cells, and studies have shown that TNFRSF18 signaling 
will modulate Tregs by regulating their generation and 
function (McHugh et al. 2002, Shimuzu et al. 2002). 
Furthermore, the suppressive activity of Treg cells can be 
abrogated by IL-6 when triggered by TLR expression on 
activated dendritic cells (DCs) (Pasare & Medzhitov 2003). 
Chemokines are secreted proteins that attract cells 
bearing chemokine receptors, such as neutrophils and 
monocytes, out of the blood-stream and into the infected 
tissue. The chemokines are classified into two major 
(CXC and CC) and two minor (C and CXC) families based 
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on structural properties and their production in 
homeostatic and inflammatory conditions. Chemokines 
produced by antigen presenting cells or immune 
responses modulating cells, can regulate the migration of 
CD4-postivie lymphocyte subsets within the body 
(Sallusto & Baggiolini 2008). Studies have shown that T 
helper type 1 cells express CCR5 and CXCR3, while T 
helper type 2 cells express CCR4 and CCR8 (Zingoni et 
al. 1998, Sallusto & Lanzavecchia 2000). CCR6 is 
expressed both in Th17 cells and Treg cells (Singh et al. 
2008, Kitamura et al. 2010). In addition, the CCL25-CCR9 
axis is essential for T cell development in the thymus 
(Vicari et al. 1997). The CXCL12-CXCR4 axis plays 
pivotal roles during early B-cell development and is 
crucial for maintaining hematopoietic stem cells’ function 
(Ara et al. 2003, Bonig et al. 2004, Tzeng et al. 2011). 
Furthermore, chemokines exhibit extraordinary specificity 
associated with certain human diseases, which suggested 
their possibility to be used as biomarkers (Zlotnik & 
Yoshie 2012).  
 
The immune reactions in parasite diseases 
 
Intracellular protozoan parasites usually stimulate typical 
Th1 immune responses, while chronic helminthes 
infections lead to characteristic Th2 immune responses 
(Díaz & Allen 2007).  Several studies have described the 
importance of cytokines and chemokines in the 
prevention and elimination of parasite infection.  With the 
tapeworm Echinococcus spp. infections, Th1-type 
cytokine IL-12 and IFN-gamma were identified to 
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successfully kill the larval stages of the parasite 
(metacestode) at the initial stages of development, 
whereas Th2 immune responses, induced by IL-4, IL-5 
and IL-10, lead to a chronic course of disease (Vuitton & 
Gottstein 2010). A combined Th1 and Th2 cytokine profile 
appears crucial for prolonged metacestode growth and 
enhanced parasite survival. The Th2-related IgE 
synthesis and mast cell activation are responsible for 
anaphylactic reactions in cystic echinococcosis, but rare 
in alveolar echinococcosis (Vuitton 2003). Low IFN-
gamma and high TNF-alpha are associated with severe 
hepatic fibrosis during Schistosoma mansoni (S. mansoni) 
infection (Henri et al. 2002, Booth et al. 2004). The 
increased expressions of IL-5, IL-10 and IL-13 are 
associated with the progression of schistosomiasis (de 
Jesus et al. 2004), while the T helper Type 2 cytokine IL-
33 guides the immune response towards a beneficial type 
2 response during Trichuris muris and Nippostrongylus 
brasiliensis infection (Humphreys et al. 2008, Neill et al. 
2010). 
Regulatory T cells are associated with parasite survival in 
helminthes infection, while controlling the infection-
associated pathology in schistosomiasis (Hesse et al. 
2004, Baumgart et al. 2006, D’Elia et al. 2009). In addition, 
Treg cells can lead to an improved parasite clearance in 
Litomosoides sigmodontis infected mice (Taylor et al. 
2005). Together TGF-beta with IL-10 has been shown to 
suppress inflammatory responses in mice infected with 
Heligmosomoides polygyrus (H. polygyrus) (Setiawan et 
al. 2007, Ince et al. 2009). In contrast, Th17 cells mediate 
the development of immunopathology during S. mansoni 
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infection (Moustapha et al. 2013), and the inhibition of an 
IL-17 production by H. polygyrus infection may protect or 
reverse inappropriate inflammation in the Schistosoma-
infected host (Eliott et al. 2004). Furthermore, IL-6 is 
essential in favoring the CD4+ T cells differentiate toward 
Th17 cells, and IL-6 can also decrease the Th2 type 
immune response and alter the Treg cells phenotype in 
mice, which will increase host susceptibility to H. 
polygyrus infection (Smith & Maizels 2014). A better 
knowledge about the differential expression patterns of 
cytokines and chemokines during the course of distinct 
parasitic infections may help to identify prognostic 
markers for disease progression or regression, and in 
addition, may help to identify therapeutic targets. 
Therefore, investigation on cytokine and chemokines 
expression profiles may lead to better understanding the 
parasite-host interplay and even evolve to new treatment 
approaches.  
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AIM of this study 
 
1 Significant impact on the diversity among immune-
related gene families is believed to be attributable to 
exposure and challenges with infectious pathogens and 
notably to repeated and persistent parasite infections. 
Variations in the promoter regions of genes can 
potentially modify the expression levels of immune 
response relevant genes by altering the function of the 
transcription pattern. Aim of this work was to identify 
SNPs in immune regulatory genes within populations that 
are naturally exposed to an array of parasites. The 
identified SNPs in the promoter regions of immune 
relevant genes may help to understand the relevance of 
sequence polymorphisms in populations exposed to poly-
parasitic diseases and for backup studies examining 
disease susceptibility. 
 
2 Cytokine and chemokine responses are pivotal to 
protect the body against foreign pathogens. Their 
expression may vary according to different parasite 
species, the duration of pathogen persistence, the 
parasite developmental stages and parasite tissue 
location within the infected host. Differential expression 
and cellular production of these immune mediators may 
find application to determine the stage of disease and 
outcome, such as cured, stable and progressive. The aim 
of this work was to clarify distinct profiles of cytokines, 
chemokines as well as antibody responses in certain 
clinically well defined stages of human Alveolar 
Echinococcosis. The distinctive responses profiles 
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together with the different clinical outcome could help to 
improve monitoring and staging of Alveolar 
Echinococcosis and may lead to the potential use of 
cytokines or chemokines as biomarkers, and it even open 
the avenue for their application as immune therapeutic 
molecules.   
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Results and Discussion 
 
The IL2 and IL2R alpha polymorphism in Gabonese 
populations  
 
A significant impact on the diversity among immune gene 
families is believed to be attributable to invasion 
maneuvers performed by parasites. Therefore variations 
in the promoter regions of immune response genes can 
potentially amend the gene expression levels either by 
changing specificity of transcription binding sites or by 
altering the kinetics of transcription initiation (Velavan et 
al. 2011). In the present work, two known SNPs 
(rs2069762T/G and rs2067006T/A) and one novel CT 
deletion (#ss410961576) at the position −83/-84 were 
identified in IL2 promoter region. None of the investigated 
SNPs altered the luciferase activity in vitro as compared 
to the major allele (rs2067006T/A was considered to be 
the major allele). In the major allele, when T allele was 
presented at the rs2069762T/G position, a potential 
binding site for the activation factor heterodimers of TCF-
11 (a transcription factor of the bzip type) and the AP-1 
protein MafG were exposed (Luna et al. 1995, Husberg et 
al. 2001, Shaulian & Karin 2002). Noteworthy, 
transcription factor AP-1 plays a pivotal role in the 
regulation of IL-2 expression (Kang et al. 1992, Jain et al. 
1992). Thus, the shifting from a T allele to a G will 
eradicate this potential binding site, which may reduce the 
binding affinity of the TCF-11/MafG complex and induce a 
relative decrease in IL-2 expression. The rs2067006T/A 
variant is positioned on the transcription site of ETS-1, 
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which belongs to ETS (E-twenty six) family. The ETS-1 
DNA-binding domain recognizes the core consensus DNA 
in target genes and acts either as a transcriptional 
activator or as repressor (Shaikhibrahim & Wernert 2012). 
Recent studies have demonstrated that ETS-1 belongs to 
a large protein complex which may restrict the stable 
FOXP3 expression in Treg cells (Polansky et al. 2010). 
FOXP3 acts as a master regulator for the natural Treg 
development and for their function (Hanel et al. 2011), 
while mature regulatory T cells expressing a non-
functional fusion protein of FOXP3 lack any suppressor 
function (Lin et al. 2007). These results suggested that 
the studied Gabonese population may have a restricted 
FOXP3 expression leading to a indirect T effector cell 
function.  
Furthermore, two known SNPs (rs12722617C/T and 
rs12722616C/T) and one novel C/T variant 
(#ss410961577) at the position −516 were identified when 
screened for the IL2R alpha (CD25) promoter region. 
Both the known SNP variants of the IL2R alpha 
(rs12722617C/T and rs12722616C/T) were observed in 
linkage in all studied individuals. No differential luciferase 
activity were found in the construct (rs12722617C/T + 
rs12722616C/T) when compared to the major allele. 
However, the novel variant (#ss410961577C/T) revealed 
a significantly increased activity in comparison to the 
construct and the major allele. This particular novel 
variant showed no relation with any putative transcription 
factor binding site, however, the variant rs12722616C/T 
which was in linkage with rs12722617C/T altered the 
transcription factor binding site TBP (TATA box binding 
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protein) and C/EBPbeta (CCAAT/enhancer binding 
protein beta). TBP (TATA binding protein) together with 
TATA associated factors (TAFS) make the transcription 
factor TFIID which binds the TATA box in combination 
with other transcription factors (Maldonado et al. 1990). 
All the above transcription factors along with the RNA 
polymerase II form a transcription initiation complex. 
Therefore, it is possible that the TATA box in the 
construct rs12722616C/T may contribute to the 
transcription initiation in vitro in Jurkat cells. The other 
transcription factor C/EBP beta is believed to modulate 
inflammatory processes. C/EBP together with Runt-
related transcription factor (RUNX) might transactivate the 
leukocyte-specific-intercellular adhesion molecule 3 
(ICAM-3) promoter (Estecha et al. 2012). Notabaly, 
ICAM-3, presented on the T cell surface induces the CD3-
mediated up-regulation of IL-2R alpha (Hernandez-
Caselles et al. 1993). A recent study has demonstrated in 
an experimental autoimmune encephalomyelitis model 
that C/EBP expression by dendritic cells (DC) influences 
the Th17 versus Treg differentiation but has little or no 
impact upon Th1 development (Tsai et al. 2011).  
The identification and validation of such polymorphisms in 
immune regulatory genes may provide a basis for future 
studies on parasite susceptibility in a given population 
where T cell functions are compromised. The role of the 
described and novel variants of IL2 and IL2R alpha still 
needs to be validated in terms of the specific role these 
play in different parasitic diseases. 
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Distinctive immune reactivity in Alveolar 
Echinococcosis 
 
Metacestode larvae of the tapeworm E. multilocularis can 
cause Alveolar Echinococcosis (AE), a severe disease, 
which, if it remains untreated, can lead to organ failure 
and fatality. E. multilocularis infection, whether in rodents 
or humans, is accompanied by chronic inflammation 
(Gottstein & Hemphill 1997). As echinococcus 
metacestodes often live as long as their hosts, efficient 
immune-evasion mechanisms should developed, which 
may allow Echinococcus spp. larvae to develop to the 
largest pathogens to dwell in mammalian internal organs 
(Conchedda et al. 2004, Vuitton & Gottstein 2010). As 
current treatment and resection will not efficiently 
eliminate the infection, many AE patients require life-long 
medication and monitoring their metacestode growth by 
imaging techniques like Magnet Resonance Tomography 
(MRT) and Positron Electron Tomography (PET). 
Previous studies have shown that different course of 
infections can elicit distinct immune responses in AE 
patients (Gottstein & Felleisen 1995). Thus, AE-specific 
biomarkers could offer a sensitive approach for diagnosis 
and surveillance. 
Immunoglobulins IgG1, IgG2, IgG4, and IgE were found 
to be highly reactive in cystic echinococcosis (CE) and in 
AE patients, which may indicate active E. multilocularis 
infestation and severe outcome of disease (Dreweck et al. 
1997). Furthermore, predominant Th2-type cellular 
immune responses together with high levels of IgG4 and 
IgE were associated with progressive and severe AE 
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(Dreweck et al. 1997). Cellular effector responses appear 
crucial for the prevention of E. multilocularis metacestode 
growth and dissemination as well as for the protection of 
the host against parasite-induced inflammation and tissue 
damage. During E. multilocularis infection, CD4-positive T 
cell responses will progressively become depressed 
(Gottstein et al. 1994, Manfras et al. 2004), while 
regulatory T cells (Treg) were found to be strongly 
expanded in mouse E. multilocularis infection (Mejri et al. 
2011).   
Interventions that boost Th1 responses resulted in 
enhanced control of the larval Echinococcus (Vuitton & 
Gottstein 2010). In chronic infection, pro-inflammatory 
Th1-type responses will slowly lessen, while Th2-type and 
Treg responses are turned on by enhanced production of 
IL-4, IL-13, TGF-beta, IL-10 and MDC/CCL22 (Jenne et al. 
1997, Aumüller et al. 2004, Vuitton & Gottstein 2010, 
Hübner et al. 2006), which may facilitate the tissue-
infiltrative growth of the parasite and its persistence in the 
human host. The inflammation associated with E. 
multilocularis infection is typically granulomatous, which is 
a CD4-postivie T cell-dependent reaction and Th17 
components were presented (Dai et al. 2004, Vuitton & 
Gottstein 2010). In addition, larval Echinococcus spp. 
infections probably induce strong regulatory responses, 
which control effector Th2-, Th1-, and possibly Th17-type 
responses. 
Th17 responses play crucial roles in host against bacterial 
and fungal infections and in the development of 
inflammatory diseases by inducing the expression of 
genes encoding pro-inflammatory cytokines (TNF, IL-6), 
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chemokines (GRO-alpha/CXCL1, ENA-78/CXCL5) as 
well as antimicrobial peptides (Ishigame et al. 2009, 
Ahmed & Gaffen 2010, Kuchroo & Awasthi 2012). The 
tissue-infiltrative growth, its proliferation and the 
dissemination of the metacestode larval stage of E. 
multilocularis resembles cancer metastasis, and also, the 
liver is the mainly affected organ by chronic metacestode 
growth.  In hepato-cellular carcinoma expanded Th17 
cells were suggested to exert immunosuppressive 
functions (Greten et al. 2012), and similarities might be 
present in Alveolar Echinococcosis. Several studies 
showed that Th17 cells exert heterogenic functions in 
tumor microenvironments with different types and at 
different stages of cancer progression or regression 
(Peters et al. 2011, Ghoreschi et al. 2011). In addition, 
high levels of the chemokine SDF-1/CXCL12 in the tumor 
micro-environment may facilitate Th17 cell trafficking and 
migration into the tumor site (Zou & Restifo 2010).  
Within the IL-17 cytokine family distinctive activities were 
observed for each member. The cytokine IL-17A showed 
tumor promoting activity by up-regulating the expression 
of pro-survival and pro-angiogenic genes, such as 
vascular endothelial growth factor (VEGF), IL-8 and IL-6 
(Tartour et al. 1999, Numasaki et al. 2003, Wang et al. 
2009); IL-17A also can indirectly stimulate anti-tumor 
activity by promoting type 1 immune responses (Martin-
Orozco & Dong 2009, Kryczek et al. 2009). The IL-17B 
may induce pro-inflammatory cytokine secretion and was 
found highly expressed in the gastro-intestinal tract, 
where E. multilocularis metacestode are mostly present 
(Li et al. 2000, Shi et al. 2000). The IL-17F was shown to 
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play a protective role in colon tumor genesis (Tong et al. 
2012). However, little is known about the cellular 
production, function and roles of the IL-17 cytokines in 
Alveolar Echinococcosis (AE).  
Decreased IL-17F levels were observed in AE patients’ 
serum as well as in cell culture supernatant of PBMC from 
AE patients' after stimulation with E. multilocularis vesicle 
antigen. These results suggest an appropriate immune 
activation against E. multilocularis antigens during the 
chronic course of AE. However, no differences were 
observed in the IL-17A levels of production in the same 
patients pointing towards a divergent immune regulation 
by the IL-17 type cytokines inducible by E. multilocularis 
antigens. Previously, IL-17A and IL-17F were shown to 
act in different way in protection against infection and in 
immune disorders as well (Ishigame et al. 2009). IL-17F 
has an earlier expression during the Th17 cell 
development than IL-17A (Lee et al. 2009), and IL-17A 
expression was more sensitive to the strength of T cell 
receptor signaling (Gomez-Rodriguez et al. 2009). It 
appears that IL-17F levels are associated with protection 
from the very beginning of infection, which is in 
accordance with the observed suppressed IL-17F levels 
in AE patients.  
For IL-17B, it was detectable in several organs with high 
expression in chondrocytes and neurons (Li et al. 2000, 
Iwakura et al. 2011, Song & Qian 2013). Furthermore, IL-
17B was suggested to play a potential pro-inﬂammatory 
role in disease processes (Yamaguchi et al. 2007). 
Elevated serum levels of IL-17B and of the soluble 
receptor component IL-17RB were observed in stable and 
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progressive AE cases and this suggested that IL-17B is 
involved in innate immune responses; it may enhance the 
migration of neutrophil granulocytes into the 
gastrointestinal tract or other epithelial structures, and 
lead to inflammatory immune reactions at targeted organs 
(Shi et al. 2000). IL-17B seems to drive early immune 
responses against various pathogens, and the activation 
of neutrophil granulocytes is the hallmark of early pro-
inflammatory immune reactions. Furthermore, over-
expression of IL-17RB was described to relate to non-
recurrence after tamoxifen treatment in breast cancer (Ma 
et al. 2004), which may point out a potential involvement 
of IL-17B in tumor regression. 
Eotaxin-1, Eotaxin-2, and Eotaxin-3 (CCL11, CCL24, and 
CCL26) are involved in the recruitment of eosinophil 
granulocytes, mast cells, and Th2 lymphocytes (Shin et al. 
2003), and CCL11/Eotaxin-1 and CCL24/Eotaxin-2 were 
found to be pivotal in the immune response against S. 
mansoni infection (Sousa-Pereira et al. 2006). Similarly in 
the present work, CCL11/Eotaxin-1 and CCL24/Eotaxin-2 
were enhanced in AE patients after activation with E. 
multilocularis metacestode antigens. With inflammation 
and immune activation, eotaxins attract eosinophil 
granulocytes to inflamed tissues and these results signify 
that such cellular effecter responses are induced by vital 
metacestode tissues, and still remain active in patients 
staged with cured AE. This indicates that not only viable 
and proliferating metacestodes of E. multilocularis, but 
residual parasite lesions will modulate cellular immune 
responses in AE patients. Similarly, elevated and 
CCL11/Eotaxin-1 and CCL24/Eotaxin-2 levels were 
Results and Discussion 
29 
 
observed in eosinophil-mediated defense mechanism 
against helminthes (Del Pozo et al. 1999).  
Furthermore, the spontaneous release of CXCL12 was 
highest in patients with progressive AE, indicating that 
CXCL12 participates in inflammatory processes with 
active AE. The CXC chemokine CXCL12 was found to be 
strongly expressed in lung and liver metastases (Müller et 
al. 2001), and CXCL12 will recruit leukocytes into infected 
tissues and promote inflammation (Berahovich et al. 
2014). An up-regulated production of CXCL12 was also 
found in rheumatoid arthritis and asthma (Karin 2010, 
Negrete-Garcia et al. 2010).  
The regulatory cytokines IL-27 can induce a strong 
proliferation of naïve human B cells, CD4+, and CD8+ T 
cells and will promote the development of Th1-type cells 
(Guzzo et al. 2010, Charlot-Rabiega et al. 2011, 
Schneider 2011). The cytokines IL-31 and IL-33 are pro-
inflammatory Th2 type cytokines and are suggested to 
play a vital role in human T-cell-mediated skin diseases 
and allergic and non-allergic diseases (Ezzat et al. 2011, 
Dillon et al. 2004). The cytokine IL-33 will activate Th2 
type helper cells, mast cells, and basophil granulocytes, 
thus supporting host defense against nematodes 
(Suzukawa et al. 2008, Yasuoka et al. 2011).  
The spontaneous but not E. multilocularis antigen-driven 
release of IL-27 increased with disease severity in AE 
patients, suggesting the presence of immune regulatory 
mechanisms which may dampen inflammation induced by 
persistent E. multilocularis. The enhanced spontaneous 
release of IL-27 in AE patients with stable and 
progressive disease may indicate the emergence of a 
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regulatory component depressing pro-inflammatory 
cytokine and chemokine responses; such regulatory IL-27 
production are likely to be induced by viable and 
persistent E. multilocularis metacestodes in AE patients.  
Several studies have shown that metacestodes of E. 
multilocularis release factors which impair the interaction 
of macrophages and T-cells in mitogen- and antigen-
induced lympho-proliferative responses (Rakha et al. 
1991, Kizaki et al. 1993). By depressing Th1-type IFN-γ 
and inflammatory MIP-1 alpha/CCL3 while activating 
immune regulatory TARC/CCL17 and RANTES/CCL5 
(Hübner et al. 2006, Kocherscheidt et al. 2008) E. 
multilocularis reduces inflammatory responses, prevents 
tissue destruction and organ damage, and facilitates 
parasite persistence within its host. Low levels of 
inflammation-associated IL-31 and IL-33 were observed 
in chronic AE supporting the notion that with parasite 
persistence, equilibrated levels of pro-inflammatory and 
regulatory cytokines and chemokines may have evolved 
to prevent disease progression and, at the same time, 
protect the host against immune-effecter cells mediated 
damage.  
Distinctive antibody responses are known to correlate 
with the clinical state of helminthes infections, with IgG4 
and IgE indicative of a Th2-type immune response and 
being prominent in chronic helminthes infections (Maizels 
et al. 1995; Mosmann & Sad 1996; Hussain et al. 1987). 
Progressively diminished E. multilocularis metacestode-
specific IgG1, IgG3 and IgE responses were observed in 
AE patients during the regression from active to stable 
and cured disease, while IgG2 and IgG4 reactivity 
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remained similarly high in stable and progressive AE. 
Several studies have shown that increased IgE correlated 
with progressive AE (Ammann et al. 1996, Dreweck et al. 
1997, Wellinghausen et al. 1999). Similarly, an enhanced 
IgE reactivity was observed in patients with progressive 
AE.  
The antibody responses specific to E. multilocularis 
vesicle antigen (EmVAg) distinguished best between 
cured, stable or progressive AE; here the antibody 
subclasses reactivity, with the exception of IgG4, 
differentiated clearly between progressive and stable AE. 
Such distinctive immune response profiles with cured, 
stable and progressive AE suggests them as useful 
makers for disease monitoring and staging. Further, the 
combination with E. multilocularis vesicle-specific 
antibody responses should provide a better immune 
monitoring during progression and regression of AE. 
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Abstract 
Background: The selection pressure imposed by the 
parasite has a functional consequence on the immune 
genes, leading to altered immune function in which 
regulatory T cells (Tregs) induced by parasites during 
infectious challenges modulate or thwart the T effector 
cell mechanism.  
Methods: We identified and investigated regulatory 
polymorphisms in the immune gene IL2 and its receptor 
IL2R alpha (also known as CD25) in Gabonese 
individuals exposed to plentiful parasitic infections.  
Results: We identified two reported variants each for IL2 
and its receptor IL2R alpha gene loci. Also identified were 
two novel variants, -83 /-84 CT deletions (ss410961576) 
for IL2 and -409C/T (ss410961577) for IL2R alpha. We 
further validated all identified promoter variants for their 
allelic gene expression using transient transfection 
assays. Three promoter variants of the IL2 locus revealed 
no significant expression of the reporter gene. The 
identified novel variant (ss410961577C/T) of the IL2R 
alpha revealed a significant higher expression of the 
reporter gene in comparison to the major allele (P<0.05). 
In addition, the rs12722616C/T variant of the IL2R alpha 
locus altered the transcription factor binding site TBP 
(TATA box binding protein) and C/EBP beta 
(CCAAT/enhancer binding protein beta) that are believed 
to regulate the Treg function.  
Conclusions: The identification and validation of such 
regulatory polymorphisms in the immune genes may 
provide a basis for future studies on parasite susceptibility 
in a population where T cell functions are compromised. 
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Background 
Parasites increase their survival rate in the host by means 
of a complex interaction with the host immune system. 
However, understanding such interaction on the part of 
the host and parasite during infections still remains a 
fundamental issue. In such processes, it is believed that 
the host regulatory T (Tregs) cells play an essential role 
[1,2]. The parasite induces a regulatory T cell (Tregs) 
population that can modulate the magnitude of effector T 
cell functions, thereby leading to a subtle immune 
response during infections [3]. The regulatory T cell 
populations remain diverse; a few of them are induced 
during infections while the others are considered to be 
natural Tregs vitally implicated in averting autoimmunity 
[4]. Tregs are believed to influence host inflammatory and 
immune responses via mechanisms of cell-to-cell contact, 
inhibitory cytokines, and cytokine deprivation [3]. 
Pathogen driven selection operating on the host immune 
genes can impose a nucleotide variation in the primed 
sequence whereby substantial changes in gene 
expression is directed [2]. Human gene expression is a 
controled transcriptional process in the promoter region of 
a given gene and is regulated by cis-acting DNA 
sequence elements. Any nucleotide alteration in the 
promoter region is likely to alter the gene expression, 
reflecting the level of susceptibility to a parasitic infection 
as well as Treg expression [5]. A number of loci are 
known to be associated with Treg activity. Genes such as 
IL10, IL13, STAT6, TNFRSF18, TLRs and FOXP3 have 
been established as key players in regulating Tregs [2,4-
7]. One such gene of interest is the interleukin 2 (IL2) and 
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its receptor IL2R alpha (CD25) that are known to 
modulate the proliferation and differentiation of T cells 
and are essential for peripheral homeostasis of the 
CD4+CD25+ Tregs [8]. 
The human IL2 is located on the q arm of the 
chromosome 4 (specifically 4q27) and its receptor IL2R 
alpha (CD25) maps to the p arm of the chromosome 10 
(specifically 10p15.1). The human IL-2 is primarily 
produced by T cells in response to antigenic stimulation 
and is a major mediator of the immune response [9]. 
Studies have demonstrated that IL-2 is essential for the 
proliferation and maintenance of Tregs and can disrupt 
Treg homeostasis [10,11], whereas the IL-2R plays a 
significant role in Treg differentiation and proliferation [12]. 
Tregs have been shown to constitutively express IL-2R 
(CD25), allowing Tregs to respond to low levels of IL-2 
produced by conventional CD4+ T cells [10,11]. The 
removal of IL-2 from activated T cells can lead to a 
deprivation of cells, which is indicated by studies on IL2-
deficient mice [13]. The IL-2 receptor has three chains, α, 
β and γ, which constitute the high affinity IL2 receptor. 
The IL2R alpha (CD25) is responsible for activating the 
IL2 signaling complex and regulates the signal 
transduction [14,15]. The IL2-R alpha subunit forms the 
largest of the three IL-2/IL2-R interfaces. Association of α 
chain with the β and γ heterodimer creates a receptor with 
a much higher affinity for IL-2 than the β and γ chains 
receptor [16]. Antigen recognition by the T cell receptor 
induces the synthesis or activation of transcription factors 
such as NFAT, AP-1, and NFκB, which are located in the 
promoter region of the IL2 gene and are essential for 
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activating its transcription [17]. Studies have pointed to 
the single nucleotide polymorphisms (SNPs) located 
within the upstream -10 kb of the IL2 gene that includes 
the promoter region, and possibly even beyond, thereby 
contributing to IL2 transcriptional properties in vivo [18]. 
The inhibition of IL2R alpha (CD25) during thymocyte 
differentiation is related to IL2R alpha promoter after 
response to pre-TCR signals and is essential for the 
specific response of mature T cells later on [19]. 
Additionally, studies have shown that SNPs within IL2R 
alpha are associated with both Grave’s disease and 
Type1 diabetes [20,21]. Reports have indicated that 
polymorphisms in the genes encoding IL2 are associated 
with ulcerative colitis, inflammatory bowel disorder, 
rheumatoid arthritis, and Behcet's disease [22-25], 
whereas the receptor of IL2, the IL2R alpha variants were 
associated with type I diabetes and multiple sclerosis 
[21,26,27]. 
In the current study, our goal is to identify regulatory 
single nucleotide polymorphisms (SNPs) in the promoter 
region of the IL2 and its receptor IL2R alpha (CD25) gene 
loci, doing so in a Sub-Saharan African population 
exposed to a wide array of parasitic diseases. In this 
study, with a view to identifying regulatory SNPs in the 
promoter regions of the IL2 and its receptor IL2R alpha 
(CD25), we sequenced the promoter region of such 
genes as were upstream of the transcriptional start site, 
using samples from 40 unrelated Gabonese individuals. 
The identified regulatory SNPs were further validated for 
their allelic gene expression, which may possibly be 
correlated with various physiological responses. 
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Methods 
Genomic DNA Isolation 
Forty DNA samples were collected from unrelated 
Gabonese individuals; informed written consent for 
participation in the study was obtained from all 
participants. Blood samples were collected from adult 
male patients with uncomplicated malaria at the Medical 
Research Unit of the Albert Schweitzer Hospital, 
Lambaréné, Gabon, between August and November 2004 
[28]. All uncomplicated malaria individuals were male 
adults living in malaria endemic countries; usually such 
individuals will not show symptoms of malaria although 
carrying parasites in their blood. The study subjects 
represent another cohort where we investigated novel 
chemotherapy against malaria [29]. To avoid 
complications arising from unnoticed pregnancy, only 
males were chosen. The study was approved by the local 
ethics committee of the International Foundation of the 
Albert Schweitzer Hospital. Genomic DNA from whole 
blood was isolated using QIAamp DNA Blood Mini kit 
(Qiagen, Hilden, Germany). 
 
Sequencing and SNP identification 
For purposes of sequencing analysis, gene and genomic 
sequences of the IL2 (NM_000586) and IL2R alpha 
(CD25) (NM_000417) were obtained from the SNPper 
database [http://snpper.chip.org/]. PCR primers were 
designed to amplify the promoter region of the gene using 
the PRIMER3 Software [http:// www 
genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi]. The 
promoter regions of the human IL2 and IL2R alpha (CD25) 
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genes were amplified by polymerase chain reaction 
(PCR). The primer pairs employed for amplifying 
promoter regions of the IL2 were IL2F: 5’-
TAAATAAGGCCATAGAATGG-3’ and IL2R: 5’- 
GTTACATTAGCCCACACTTA -3’. The primer pairs 
employed to amplify promoter regions of IL2R alpha were 
IL2RF: 5’- GATCCACCCACCTTGGTCTA -3’ and IL2RR: 
5’-GGCAGCCAGGCACCATGATGAAC -3’ (MWG Operon, 
Germany). In brief: PCR were carried out in 20 l reaction 
volumes with 5ng of genomic DNA, 1x PCR buffer (20 
mM Tris-HCl pH 8.4, 50 mM KCl, 1.5 mM of MgCl2; 
Qiagen), 0.125mM of dNTPs, 0.5mM of each primer and 
1 U Taq DNA polymerase (Qiagen, Hilden, Germany) on 
a PTC-200 Thermal cycler (MJ Research, USA). Thermal 
cycling parameters for the amplification of both IL2 and 
IL2R alpha were as follows: initial denaturation at 94 °C 
for 5min, followed by 40 cycles of 15 sec at 94 °C 
denaturation, 60 sec at 60 °C annealing temperature, 60 
sec at 72 °C extension, followed by a final extension of 10 
min at 72 °C.  PCR products were cleaned up using Exo-
SAP-IT (USB, Affymetrix, USA) and 1µl of the purified 
product was directly used as templates for sequencing, 
using the BigDye terminator v. 2.0 cycle sequencing kit 
(Applied Biosystems, USA) on an ABI 3130 XL DNA 
sequencer, according to the manufacturer’s instructions. 
Polymorphisms in the promoter regions were identified by 
assembling the sequences, the respective reference 
sequences being obtained from the SNP per database 
(http://snpper.chip.org) using Codon code Aligner 4.0 
software (http://www.codoncode.com/), and were then 
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reconfirmed visually from their respective 
electropherograms. [stimmt diese Korrektur?  Ja!! ] 
 
Cloning and construct preparation 
The SNPs identified in the promoter regions had their 
polymorphism status reconfirmed by subsequent cloning 
procedures. Those genomic DNA sequences identified as 
having SNPs in the promoter regions of the IL2 and IL2R 
alpha were amplified with infusion primers (flanks a 15bp 
homology to the linearized pGL3 vector) and were then 
cloned to a linearized pGL3 basic vector. In brief, PCR 
amplifications were carried out in 50 l reaction volumes 
under the same program conditions as mentioned above. 
The amplified PCR products was analyzed by 
electrophoresis in 1.5% agarose gels, using a 100 bp 
DNA ladder molecular size marker (Invitrogen, Karlsruhe, 
Germany), and PCR -products were gel eluted and 
purified using a Nucleospin kit (Macherey-Nagel, Düren, 
Germany) before being cloned to the pGL3 basic vector 
using Infusion advantage PCR cloning kit (Clonetech, 
Mounatain view, CA). Plasmids were isolated using 
QIAprep® Spin Miniprep Kit (Qiagen, Hilden, Germany). 
To ensure accuracy of the sequenced promoter regions, 
several independent plasmids containing inserts were 
sequenced in both directions using appropriate primer 
pairs. The plasmid exhibiting the confirmed polymorphism 
was transformed into one shot E. coli (Invitrogen, 
Karlsruhe, Germany). Two independent colonies were 
selected from these transformations and maxi prep was 
performed using Endofree plasmid maxi kit (Qiagen, 
Hilden, Germany). 
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Transient transfection assays 
We tested the activities of the observed polymorphic 
promoters for both IL2 and IL2R alpha, using Jurkat T cell 
lines. Basically, four independent transfection 
experiments for each construct in duplicates were 
performed with Jurkat T cells (DSMZ, Braunschweig, 
Germany). Jurkat T cells (0.8X10 6 cells/µl) were grown in 
a RPMI 1640 (Sigma-Aldrich, Hamburg, Germany) 
supplemented medium containing 10% FBS, 2mM L-
Glutamine, and 1% Streptamycin-pencillin substrate 
(Invitrogen, Karlsruhe, Germany). Jurkat cells (0.8X10 6 
cells/µl) were transfected with TransIT reagent (Mirus Bio, 
Madison, USA) as recommended by the manufacturer. In 
brief: 120µl of TransIT reagent was added to 3ml of RPMI 
1640 serum free medium (Sigma-Aldrich, Hamburg 
Germany), this being then incubated for 20 min at room 
temperature. Each of the 24 well plates was then seeded 
with 0.5ml (0.8X10 6 cells/µl) of Jurkat T cells, along with 
500ng of plasmid DNA constructs and 20ng of Renilla, 
before being allowed to incubate for 20 minutes. After 
incubation, 52µl of TransIT+RPMI serum free medium mix 
were suspended across each well. The whole procedure 
was performed in 2X24 well plate formats. After 24 hours, 
one plate was induced with 20ng/ml Phorbol 12-myristate 
13-acetate (PMA, Sigma-Aldrich, Hamburg, Germany) as 
well as 25µg/ml Concanavalin A (Sigma-Aldrich, Hamburg, 
Germany). After 24 hours, cells were harvested by 
centrifugation, then washed twice with phosphate-
buffered saline and lysed in 100µl of 1x passive lysis 
buffer (Promega, Mannheim, Germany). After incubation 
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for 20 min at room temperature on a rocking platform, 
10µl of the lysate was used to measure luciferase activity 
in the SIRIUS luminometer (Berthold detection system, 
Pforzheim, Germany). We employed the dual luciferase 
reporter assay system (Promega, Mannheim, Germany). 
For each experiment, a plasmid expressing constitutively 
Renilla luciferase in low amounts was used as a positive 
control [30], while a promoterless plasmid (pGL3 basic) 
was integrated as a negative control. Each construct was 
measured 8 times, then both stimulated and non 
stimulated with two different DNA preparations. Relative 
luciferase activity was calculated as luciferase 
firefly/luciferase Renilla multiplied by 1000. 
 
Transcription factor binding search 
An extensive search for transcription factor binding sites 
for the observed SNPs in the promoter region was 
performed using a TF-Search online tool 
(http://www.gene-regulation.com/pub/programs/alibaba2) 
that utilizes TRANSFAC 4.0. 
 
Statistical analysis 
Data were normalized and then analyzed by StatView 
(http://www.statview.com). The mean ratio 
(Luciferase/Renilla) across all measurements was 
considered for purposes of calculating relative luciferase 
activity. The luciferase activity of the two different IL2 and 
IL2R alpha (CD25) promoter variants was comparatively 
analyzed by a t-test (before and after stimulation). In 
addition, each construct’s activity was compared to the 
activity of the major allele (common alleles) in both an 
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induced and a non induced state. The statistically 
significant level was set as 0.05. 
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Results 
All forty subjects were sequenced for the entire promoter 
region of the IL2 and IL2R alpha (CD25) and were then 
investigated for described and novel SNPs. For the IL2 
promoter region, two predescribed SNPs (rs2069762T/G 
and rs2067006T/A) were observed. In addition, we 
observed a novel CT deletion at the position -83/-84 in 
one individual. This novel SNP was submitted to the 
SNPper database and a corresponding ID obtained 
(#ss410961576). The corresponding references SNP ID 
(#rs); observed allele frequencies from the investigated 
IL2 gene are summarized in Table 1. In order to 
characterize these variants in terms of function, a 
transient transfection assay were performed using Jurkat 
T cells. The activity of the three different IL2 promoter 
variants analyzed by luciferase activities is compared in 
Fig. 1. The p-values of the two observed SNP constructs 
of the IL2 variant remained insignificant in comparison to 
the major allele before and after stimulation (P > 0.05). 
When explicitly examined for a transcription factor binding 
site in the observed variants of IL2, the rs2067006T/A 
variant was found to be positioned on the transcription 
site ETS-1, which is a member of the ETS (E-twenty six) 
family of transcription factors that function as 
transcriptional activators or repressors in numerous 
genes believed to be involved in stem cell development, 
cell senescence, and death. The other two variants 
(#ss410961576CTdel and rs2069762T/G) do not alter any 
putative transcription factor binding site. 
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Table 1. Genetic variants identified in the promoter regions of the IL2 
gene locus 
 
 
 
 
 
 
 
a: Frequency corresponds for both allele and genotypes; b: YRI: 
Yoruba population representing Sub- Saharan African individual group, 
CEU: European, CHB: Han Chinese; NA: data not available 
  
SNP (rs#) Position Polymorphism Flanking sequences Genotype
Analysed 
individuals
Allele Frequency a
Frequencies                                       
(Hapmap YRI, CEU, CHB)b
ss410961576 -83,84 CT deletion ATTTT [CT/-] GAGTT CT/CT 39 CT 0.975
del/del 1 del 0.025
rs2069762 -100 T >G TTTTA [T/G] GACAA TT 38 T 0.950 0.966, 0.768 , 0.733
TG 2 G 0.050 0.034, 0.232, 0.267
rs2067006 -191 T>A TGTTT [T/A] ATCAA AT 0 T 0.000 0.000, 0.000, 0.000
AA 40 A 1.000 1.000, 1.000, 1.000
NA
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Figure 1:  Comparison of the activity of the three identified IL2 
promoter variants analyzed by luciferase activities. The ratio of the 
relative light units (firefly/renilla) is given. P values are calculated by t-
Test from four different experiments performed in duplicates with two 
different DNA preparations. Each construct was induced by PMA and 
ConA. The letters indicate the presence of mutations T/G, CT del and 
T/A. 
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For the IL2R alpha (CD25), two described variants in the 
promoter region (rs12722617C/T and rs12722616C/T) 
were observed. In addition, we observed a novel C/T 
variant at the position -409 in two individuals. This novel 
SNP was submitted to the SNPper database and a 
corresponding ID was obtained (#ss410961577). The 
corresponding references SNP ID (#rs); observed allele 
frequencies from investigated IL2R alpha (CD25) are 
summarized in Table 2. The activity of the three different 
IL2 promoter variants analyzed by luciferase activities is 
compared in Fig. 2. The variant rs12722617C/T and 
rs12722616C/T were observed to be in absolute linkage 
in all the individuals analyzed. The p-values of the SNP 
construct (rs12722617C/T + rs12722616C/T) of the IL2R 
alpha variant remained insignificant in comparison to the 
major allele before and after induction (P >0.05), but 
remained significant when compared to the new variant in 
a stimulated state (P<0.0005). The observed novel 
variant #ss410961577C/T showed significantly increased 
activity in comparison to the major allele (P<0.05). When 
explicitly examined for a transcription factor binding site in 
the observed variants of IL2R alpha (CD25), two variants 
(rs12722617C/T and #ss410961577C/T) were found not 
to alter any putative transcription factor binding site. 
However, the SNP variant (rs12722616C/T), which was in 
linkage disequilibrium (LD) with rs12722617C/T, is 
positioned at the transcription factor binding site TBP 
(TATA box binding protein) and C/EBP beta 
(CCAAT/enhancer binding protein beta). 
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Table 2. Genetic variants identified in the promoter regions of the IL2R 
alpha (CD25) gene locus 
 
 
 
 
 
 
a: Frequency corresponds for both allele and genotypes; b: YRI: 
Yoruba population representing Sub- Saharan African individual group, 
CEU: European, CHB: Han Chinese; NA: data not available 
 
  
SNP (rs#) Position Polymorphism Flanking sequences Genotype
Analysed 
individuals
Allele Frequency a
Frequencies                                       
(Hapmap YRI, CEU, CHB)b
rs12722617 -398 C >T TTCGC [C/T] GCATC CC 35 C 0.875 0.932, 1.000, NA
CT 5 T 0.125 0.068, 0.000, NA
ss410961577 -409 C >T GGATC [C/T] TTCAG CC 38 C 0.950
CT 2 T 0.050
rs12722616 -516 C >T AACAC [C/T] TTATA CC 35 C 0.875 0.924, 1.000, 1.000
CT 5 T 0.125 0.076, 0.000, 0.000
NA
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Figure 2:  The activity of the three identified IL2R alpha promoter 
variants as compared by luciferase activities. The ratio of the relative 
light units (firefly/renilla) is given. P values are calculated by t-Test in 
four different experiments performed in duplicates with two different 
DNA preparations. Each construct was induced by PMA and ConA. 
The letters indicate the presence of polymorphic variants. 
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Discussion 
The underlying idea of the current study is to understand 
how regulatory SNPs in populations that are naturally 
exposed to array of parasites contribute to immune 
outcome. A significant impact on diversity among immune 
gene families is believed to be attributable to invasion 
maneuvers performed by the parasites. Therefore, 
variations in the promoter regions of these immune 
system genes can potentially amend the gene expression 
levels, either by changing specificity of transcription 
binding sites or by altering the kinetics of transcription 
initiation [7]. In our current study, we identified two known 
SNPs (rs2069762T/G and rs2067006T/A) and one novel 
CT deletion (#ss410961576) at the position -83/-84 when 
screened for IL2 promoter region. None of the 
investigated SNP constructs revealed differential 
luciferase activity compared to the major allele. In the 
current investigation, the IL2 variant (rs2067006T/A) was 
considered to be the major allele, as all the individuals 
were found to harbor this particular variant. When 
compared to the NCBI HapMap database, the 
frequencies of the observed SNP variants (rs2067006T/A 
and rs2069762T/G of IL2) were in accordance with the 
Yoruba population of Nigeria, which represents a Sub 
Saharan African group. The rs2067006T/A variant is 
positioned on the transcription site ETS-1, a member of 
the ETS (E-twenty six) family of transcription factors. The 
ETS-1 DNA-binding domain recognizes the core 
consensus DNA in target genes and acts either as 
transcriptional activators or repressors [31]. Recent 
studies have demonstrated that ETS-1 belongs to a large 
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protein complex which binds to the Treg-specific 
demethylated region (TSDR) in the FOXP3 locus, thereby 
restricting the stable FOXP3 expression in the Tregs [32]. 
FOXP3 is described as a master regulator of natural 
Tregs development and function [4], while mature 
regulatory T cells expressing a non-functional fusion 
protein of FOXP3 lack any suppressor function [33]. Since 
all the investigated individuals inherited this variant, we 
believe that the studied population may have a restricted 
FOXP3 expression leading to a subtle T effector cell 
function. 
In our study we also identified two known SNPs 
(rs12722617C/T and rs12722616C/T) along with one 
novel C/T variant (#ss410961577) at the position -516 
when screened for the IL2R alpha (CD25) promoter 
region of the IL2R alpha. Both predescribed SNP variants 
of the IL2R alpha (rs12722617C/T and rs12722616C/T) 
were observed in linkage in all studied individuals. We did 
not observe a differential luciferase activity compared to 
the major allele for the construct (rs12722617C/T + 
rs12722616C/T). However, the identified novel variant 
(#ss410961577C/T) revealed significant increased activity 
in comparison to the constructs with the major allele. This 
particular novel variant did not alter any putative 
transcription factor binding site. But the variant 
rs12722616C/T, which was in LD with rs12722617C/T, 
altered the transcription factor binding site TBP (TATA 
box binding protein) and C/EBP beta (CCAAT/enhancer 
binding protein beta). The TATA box is a type of promoter 
sequence that indicates the transcriptional start site 
whereby a genetic sequence can be read and decoded. It 
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is named after the conserved DNA sequence TATAAA. 
TBP (TATA binding protein) together with TATA 
associated factors (TAFS) make the transcription factor 
TFIID which binds the TATA box in combination with 
other transcription factors (TFIIB, TFIIA, TFIIE, TFIIF, 
TFIIH) [34]. All the above transcription factors along with 
RNA polymerase II enzyme form a transcription initiation 
complex. Therefore, it is possible that the TATA box in the 
construct rs12722616C/T contributes to the transcription 
initiation in vitro in the Jurkat cells. The other transcription 
factor C/EBP beta (CCAAT/enhancer binding protein beta) 
is believed to modulate inflammatory processes. A recent 
study has demonstrated in an experimental autoimmune 
encephalomyelitis model that C/EBP expression by 
dendritic cells (DC) influences Th17 versus Treg 
differentiation but has little or no impact upon Th1 
development [35]. Examining the HapMap database, all 
the frequencies of reported variants of the IL2R alpha loci 
were found to be in accordance with the frequencies in 
the Yoruba population. 
Human IL2 and its receptor IL2R alpha are described as 
constituting a potent T cell growth factor and are mainly 
produced by activated CD4+ T cells, though also by naïve 
CD8+ T cells, dendritic cells, and thymic cells [36]. 
Human IL-2 is considered to be vital for the development 
of CD4+CD25+ regulatory T cells [37]. Also, studies have 
demonstrated that IL-2 potentially plays a role in the 
thymic development of Tregs [38,39]. Studies have shown 
that polymorphisms in the IL2 are associated with many 
diseases, including auto immune diseases. Recent 
studies have demonstrated that the studied IL2 promoter 
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variant (rs2069762T/G) is associated with Helicobacter 
pylori infection [40], multiple sclerosis [41], pathogenesis 
of childhood lymphoma [42], pathogenesis of new-onset 
diabetes after transplantation (NODAT) [43], measles-
specific cellular immunity [44], a higher risk of acute 
rejection episodes during kidney transplantation [45] and 
in allergic disorders [46] . However, the role of the 
described and novel variants of IL2 and IL2R alpha in this 
study needs to be validated in terms of the specific role 
these play in different parasitic diseases. 
 
Conclusions 
In summary, the regulatory SNPs identified in this current 
study will provide useful information for understanding the 
relevance of sequence polymorphisms in populations 
exposed to many parasitic diseases and may serve as a 
basis for backup studies examining disease susceptibility  
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Abstract 
Alveolar Echinococcosis (AE) caused by the cestode 
Echinococcus multilocularis, is a severe helminth infection 
of man, where unrestricted parasite growth will ultimately 
result in organ failure and fatality. The tissue-infiltrative 
growth of the larval metacestode and the limited efficacy 
of available drugs complicate successful intervention in 
AE; patients often need lifelong medication, and if 
possible, surgical resection of affected tissues and organs. 
Resistance to AE has been reported, but the 
determinants which confer protection are not known. ln 
this study, we analyzed in patients at distinct stages of 
Alveolar Echinococcosis, that is cured, stable and 
progressive AE, as well as in infection-free controls, the 
cellular production and plasma levels of pro-inflammatory 
cytokines lL-17A, lL-17B, lL-17F and their soluble 
receptors lL-17RA (slL-17RA) and IL-17RB (sIL-17RB). 
Significantly elevated levels of IL-17B and slL-17RB were 
observed, whilst lL-17F and lL-17RA were reduced in 
patients with AE. Similarly, the cellular production of lL-
17F and slL-L7RA in response to E. multilocularis 
antigens was low in AE patients, while levels of slL-17RB 
were highly enhanced. These observations suggest 
immune-modulating properties of E. multilocularis on lL-
17 cytokine-mediated pro-inflammatory immune 
responses; this may facilitate the tissue infiltrative growth 
of the parasite and its persistence in the human host. 
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1. Introduction 
Alveolar Echinococcosis (AE) of man can develop 
following the ingestion of eggs of Echinococcus 
multilocularis. Egg-hatched larvae will migrate into various 
host tissues, mainly liver, and their proliferative and 
tissue-infiltrative growth as metacestode larvae will cause 
damage and ultimately organ failure. Dissemination of 
cells of metacestode larvae may initiate metastasis-like 
parasite growth in secondary organs such as lungs and 
CNS which impairs surgical resection [1]. Since current 
chemotherapy with imidazoles is only parasitostatic, AE 
cases with inoperable parasite lesions require life-long 
medication [2].  
In some cases of human AE, a spontaneous healing of 
the disease was observed [1, 3]. Such abortive cases are 
characterized by calcified parasite lesions suggesting the 
generation of immune responses which are able to limit 
parasite growth in humans [4]. Previous studies have 
shown that Th1- and Th2-type immune responses might 
be important for clearance of the infection and are 
associated with the chronic and progressive course of 
disease [4]; however, knowledge about the crucial 
determinants which limit parasite growth and disease 
progression remains scarce. IL-5 is the predominant 
cytokine expressed by PBMCs in AE patients [5], and 
Th2-type IL-3, IL-5, and IL-10 were enhanced in severely 
ill AE patients [6–8] while E. multilocularis antigen-
induced IFN-γ and spontaneous IL-12 production were 
decreased [9, 10]. Most important, IL-12 and IFN-γ 
inhibited larval growth and metacestode dissemination in 
E. multilocularis-infected mice [11, 12], while the 
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application of IFN-γ stopped disease progression in an 
AE patient [13].  
Th1- and Th2-type immune responses in AE have 
extensively been studied, but pro-inflammatory and 
regulatory chemokines as well as Th17-type cytokines 
have received less attention. Immune responses against 
metacestode larvae of E. multilocularis will create 
persistent sites of inflammation and the formation of peri-
parasite granulomas. The chemokines CCL3/MIP-1α, 
CCL4/MIP-1β, and CCL5/RANTES were highly elevated 
in AE patients [14], while mononuclear cells isolated from 
peri-parasite host granulomas secreted high amount of IL-
10 and low amounts of IFN-γ disclosing an immune 
regulation which will counteract inflammatory responses 
in AE patients [15].  
The role of IL-17 cytokines and Th17-type immune 
responses in AE disease is yet unexplored. The six family 
members identified (IL17A-F) exert mostly 
proinflammatory activities [16]. IL17A and IL17F, 
mediators of the recently described proinflammatory 
Th17-type immune responses, have been associated with 
inflammatory disorders like rheumatoid arthritis and 
inflammatory bowel disease [17, 18] but also with 
protection against extracellular bacteria and fungi [19, 20]. 
We analyzed levels of proinflammatory IL-17 members 
(IL-17A, IL-17B and IL-17F) as well as their soluble 
common receptors (IL-17RA and IL-17RB) in clinically 
staged AE patients, that is, cured, stable, and progressive 
AE, and in infection-free controls. The altered 
concentrations of IL-17B, Th17-type cytokine IL-17F, and 
their soluble receptors at distinct stages of AE disease 
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suggest that these pro-inflammatory cytokines may 
contribute to the clinical outcome of E. multilocularis 
infection. 
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2. Materials and Methods 
2.1. Study Groups  
The patient cohort consisted of 93 patients (58 
females/35 males) diagnosed with Alveolar 
Echinococcosis at University of Ulm Clinics/Germany. 
The AE patients’ mean age was 57 years, ranging from 
17 to 83 years. Blood samples from 12 AE-free 
individuals from the Blood Transfusion Centre at 
University Clinics Tübingen served as controls. The UKT 
Tübingen and University of Ulm Clinics are situated in the 
federal state of Baden-Wurttemberg of Germany, a region 
endemic for E. multilocularis infections. In the AE patient 
groups, 23 cases were diagnosed with cured, 64 with 
stable, and 6 with progressive AE. The classification of 
AE patients in different clinical stages of AE was 
accomplished according to the World Health 
Organization- (WHO-) PNM (P = parasitic mass in the 
liver, N = involvement of neighboring organs, and M = 
metastasis) system previously published by Kern and 
coworkers [21]. Curative resection, stable disease, 
progressive disease, or presence of an apparently dead, 
fully calcified lesion was established by magnetic 
resonance imaging on the basis of lesion size and 
morphology at the respective follow-up intervals. This 
classification has been used for follow-up studies of AE 
patients [22, 23]. Written consent was obtained from all 
participating patients, and this study was approved by the 
Ethics Review Board at University of Ulm Clinics (Ethik-
Kommissions Antrag number 71/2004).  
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2.2. In Vitro Culture of Echinococcus Multilocularis 
Metacestodes 
E. multilocularis metacestodes were cultivated at 37°C, 5% 
CO2 and saturated humidity as previously described [14]. 
For the generation of single-cell lines, in vitro maintained 
E. multilocularis metacestode tissue blocks were cut into 
small pieces and cultured in RPMI 1640 supplemented 
with 5% FCS and 1% antibiotic-antimycotic solution (PAA, 
Cölbe, Germany) in cell tissue culture flasks at 37%, 5% 
CO2, and saturated humidity. After 3 days cell culture 
flasks were washed with RPMI supplemented with 
antibiotics (as above) to obtain flask surface-adherent E. 
multilocularis derived cells. Adherent E. multilocularis 
single-cells (EmZ) were grown as above and flask 
cultures were split when cell overgrowth was observed. 
Cells were harvested, centrifuged, and stored at −80◦C 
for further use.  
 
2.3. Antigen Preparation  
The preparation of E. multilocularis metacestode and 
Ascaris lumbricoides antigens was performed as 
described previously [14]. Briefly, E. multilocularis 
metacestode tissues or adult A. lumbricoides were 
homogenized using a Ten Broek tissue grinder and 
subsequently ultrasonified (30% intensity, pulse 1 second 
for 8 minutes). The Echinococcus metacestode or Ascaris 
adult worm suspensions were then centrifuged at 4°C, 
sterile filtered (0.22 μm) and kept at −20°C. For E. 
multilocularis vesicle antigen preparation, entire E. 
multilocularis vesicles were collected, separated from in 
vitro culture medium, and vesicles were ruptured by 
Publications 
88 
 
sonication pulses (30% intensity, pulse 1 s for 1 min). 
Such disrupted vesicles were then homogenized, that is, 
grinded with a Ten-Broek tissue grinder on ice until a 
homogenous liquid extract was produced, then sonicated 
again (30% intensity, pulse 1 s for 8min) and thereafter 
the vesicle homogenate was centrifuged at 5000 g for 30 
min at 4°C. The supernatant was sterile filtrated (0.22 μm) 
and stored at −70°C. For single-cell E. multilocularis 
antigen preparation, in vitro grown adherent 
E.multilocularis single-cells were detached from the 
culture flask surface, and were collected and separated 
from in vitro culture medium by centrifugation (1.500 g for 
5 minutes). The cell pellet was homogenized, that is, 
grinded with a Ten-Broek tissue grinder on ice until a 
homogenous liquid extract was produced, then sonicated 
(30% intensity, pulse 1 s for 8min) and thereafter the cell 
homogenate was centrifuged at 5000 g for 30 min at 4°C. 
The supernatant was sterile filtrated (0.22 μm) and stored 
at −70◦C. Protein concentrations were determined by 
bicinchoninic acid (BCA) protein determination (Pierce, 
Rockford, IL, USA). Entamoeba histolytica antigen (EhAg) 
was a kind gift of B. Walderich (Institute for Tropical 
Medicine, Tübingen, Germany).  
 
2.4. Isolation of Peripheral Blood Mononuclear Cells 
(PBMC) 
PBMC and plasma from AE patients and control 
individuals were isolated by means of Ficoll density 
gradient centrifugation as described previously [24]. 
PBMC were adjusted to a concentration of 2 × 106 cells 
per mL and dispersed into 48 well tissue culture plates 
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with 0.5mL per well in RPMI 1640 supplemented with 5% 
FCS and 1% antibiotic-antimycotic solution. PBMC were 
stimulated for 24 and 48 hours with either 5 μL E. 
multilocularis metacestode antigen (Em, stock 
concentration 60 μg/mL), E.multilocularis single-cell 
antigen (EmZ, stock concentration 60 μg/mL), E. 
multilocularis vesicle antigen (EmV, stock concentration 
60 μg/mL), Ascaris antigen (Asc, stock concentration 3.7 
μg/mL), or E. histolytica antigen (Eh, stock concentration 
100 μg/mL) or left unstimulated (base) at 37°C, saturated 
humidity, and 5% CO2. Cells and cell culture supernatant 
were harvested, separated by centrifugation, and stored 
at −80°C.  
 
2.5. Determination of Cytokine and Chemokine 
Concentrations 
Cell culture supernatants and plasma were stored at 
−80°C before use. Cytokine and chemokine 
concentrations were determined by sandwich enzyme-
linked immunosorbent assay (ELISA) kits for IL-17A, IL-
17B, IL-17F, IL-17RA, and IL-17RB (R&D Systems, MN, 
USA). The assays were performed according to the 
manufacturers’ guidelines. Conversion of optical densities 
(OD) to final concentrations (pg/mL) was calculated by 
using cytokine-specific standard curves. 
 
2.6. Data Analysis and Statistics  
The statistical package JMP 9.0 (SAS Institute, 
Heidelberg, Germany) was used for statistical analyses. 
Significant differences of cytokine and chemokine 
concentrations were determined by analysis of variance 
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(ANOVA) and Tukey’s test. Due to multiple comparisons 
the level of significance was adjusted by the Bonferroni-
Holm method. 
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3. Results 
 
3.1. Plasma Levels of Proinflammatory IL-17 Family 
Members and Soluble Receptor Components in AE 
Patients and Infection-Free Controls  
Plasma concentrations of proinflammatory IL-17 family 
members IL-17A, IL-17B, IL-17F and their common 
soluble receptor subunits, sIL-17RA and sIL-17RB, were 
quantified in AE patients with different states of disease 
and in infection-free controls.  
The levels of IL-17B were lowest in healthy controls and 
were significantly increased in all AE patient groups (P < 
0.01 and P < 0.001) (Figure 1(a)). Within the AE patient 
group, lowest concentrations of IL-17B were detected in 
cured cases of AE, while highest concentrations were 
observed in progressive cases. Soluble IL-17RB levels 
were lowest in non-infected controls and highly elevated 
in all AE patient groups, while IL-17RB did not differ 
between patient groups (Figure 1(b)). Similar plasma 
concentrations of IL-17A were observed within AE patient 
groups and infection-free controls (Figure 2(a)).   
In contrast, the concentrations of IL-17F, and its soluble 
receptor IL-17RA were the highest in infection-free 
controls. While plasma levels of IL-17F were significantly 
reduced in stable and progressive cases of AE (P < 0.05), 
significantly decreased levels of soluble IL-17RA 
concentrations were detected in all AE patient groups (P 
< 0.01 and P < 0.001) (Figures 2(b) and 2(c)).  
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Figure 1: Plasma concentrations of interleukin (IL)-17B (part a) and 
soluble receptor IL-17RB (part b) in Alveolar Echinococcosis (AE) 
patients and in infection-free controls (CTRL). The patients were 
grouped according to their state of infection, that is, cured, stable, or 
progressive (Prog.) Alveolar Echinococcosis. The plasma 
concentrations are shown as the mean values in pg/mL with the 95% 
upper and lower confidence interval. The level of significance was 
adjusted by the Bonferroni-Holm method. Significant differences 
between the groups are indicated (*P < 0.05, **P < 0.01, and ***P < 
0.001).
 
Figure 2: Plasma concentrations of interleukin (IL)-17A (part a) and IL-
17F (part b) and of soluble IL-17RA (part c) in Alveolar Echinococcosis 
(AE) patients and infection-free controls (CTRL). Patients were 
grouped according to their state of infection, that is, cured, stable, or 
progressive (Prog.) Alveolar Echinococcosis. The plasma 
concentrations are shown as the mean values in pg/ml with the 95% 
upper and lower confidence interval. The level of significance was 
adjusted by the Bonferroni-Holm method. Significant differences 
between the groups are indicated (*P < 0.05, **P < 0.01, and ***P < 
0.001).  
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3.2. Echinococcus multilocularis Antigen-(EmAg-) 
Induced Cellular Production of Soluble IL-17RA 
from AE Patients and Controls 
The production of soluble IL-17RA, sIL-17RB, and IL-17F 
by peripheral blood mononuclear cells (PBMC) was 
investigated in AE patients and controls. Stimulation of 
PBMC with Echinococcus multilocularis vesicle (EmV) 
antigen for 24 hours did not result in cellular production 
differences of soluble IL-17RA between AE patients and 
infection-free control groups (Figure 3(a)). In addition, no 
differences within the AE patient groups could be 
observed. After 48 hours of stimulation a decreased 
cellular production of sIL-17RA by PBMC from all AE 
patient groups was observed, with production levels in 
healthy controls and stable AE cases being significantly 
different (P < 0.01) (Figure 3(b)). Production of cytokines 
and soluble receptors levels in response to Ascaris 
lumbricoides (AscAg) or to Entamoeba histolytica (EhAg) 
antigens did not differ between AE patient groups and 
controls.  
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Figure 3: Echinococcus multilocularis antigen induced cellular 
production of soluble interleukin-17 receptor A (sIL-17RA) by 
peripheral blood  mononuclear cells (PBMCs) from Alveolar 
Echinococcosis (AE) patients and infection-free controls (CTRL). 
Patients were grouped according to their state of infection, that is, 
cured, stable, or progressive (Prog.) Alveolar Echinococcosis. PBMCs 
from patients and controls were stimulated with E. multilocularis 
vesicle extract (EmV) for 24 (part a) and 48 hours (part b) or left 
without stimulation. Cytokine concentrations in cell culture supernatant 
were quantified by specific ELISA. The EmAg-induced cytokine 
production (Netto Prod.) was calculated by subtracting the cytokine 
production in not stimulated PBMC cultures from EmV-stimulated 
cytokine production. The cytokine production is shown as mean values 
in pg/mL with the 95% upper and lower confidence interval. The level 
of significance was adjusted by the Bonferroni-Holm method. The 
significant differences between groups are indicated (*P < 0.05, **P < 
0.01, ***P < 0.001). 
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3.3. EmAg-Induced Cellular Production of 
Soluble IL-17RB from AE Patients and Controls  
PBMC from progressive cases of AE produced high 
amounts of sIL-17RB following 24 and 48 hour stimulation 
with Echinococcus multilocularis vesicle (EmV) and 
single-cell (EmZ) extract (Figures 4(a) and 4(b)). The 
production difference between PBMC from progressive 
cases and the other groups was more prominent after 24 
hours of stimulation than after 48 hours. The cellular 
production levels of sIL-17RB from infection-free controls 
and cured and stable cases did not differ in response to 
EmV or EmZ stimulation. Vesicle components, that is, 
parts of the laminated and germinal layer, but also hydatid 
fluid, which constitutes the largest volume of vesicles, 
may have conferred the observed effects on sIL-17RB 
production. The single-cell line extract (EmZ) may contain 
pro-inflammatory components from the inner germinal 
layer of the metacestode.  
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Figure 4A  
Figure 4B  
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Figure 4: Echinococcus multilocularis antigen induced cellular 
production of soluble interleukin-17 receptor B (sIL-17RB) by PBMC 
from Alveolar Echinococcosis (AE) patients and infection-free controls 
(CTRL). Patients were grouped according to their state of infection, 
that is, cured, stable, or progressive (Prog.) Alveolar Echinococcosis. 
PBMCs from patients and controls were stimulated with Echinococcus 
multilocularis single-cell extract (EmZ) (a) and vesicle extract (EmV) (b) 
for 24 and 48 hours or left unstimulated. Cytokine concentrations in 
cell culture supernatant were determined by specific ELISA. The 
EmAg-induced cytokine production (Netto Prod.) was calculated by 
subtracting the cytokine production in not stimulated PBMC (Baseline) 
cultures from EmV-stimulated cytokine production (Brutto production). 
The cytokine production is shown as mean values in pg/mL with the 95% 
upper and lower confidence interval. The level of significance was 
adjusted by the Bonferroni-Holm method. The significant differences 
between groups are indicated (*P < 0.05, **P < 0.01, and ***P < 0.001). 
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3.4. EmAg-Induced Cellular Production of IL-17F 
in AE Patients and Controls  
Cellular production of IL-17F in response to Echinococcus 
multilocularis vesicle extract (EmV) for 24 and 48 hours 
was the highest in the control group (Figure 5). Compared 
to healthy controls, PBMC from all AE patient groups 
produced significant lower amounts of IL-17F in response 
to antigen stimulation (P < 0.05 and P < 0.001) (Figure 5). 
Stimulation of PBMC with EmV resulted in a similar IL-
17F production in the three clinical AE patient groups 
(Figure 5). The IL-17F production by PBMC in response 
to E. multilocularis single-cell extract showed no 
difference between the studied groups (data not shown).  
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Figure 5: Echinococcus multilocularis antigen- (EmAg-) induced 
cellular production of interleukin-17F (IL-17F) by PBMC from Alveolar 
Echinococcosis (AE) patients and infection-free controls (CTRL). 
Patients were grouped according to their state of infection, that is, 
cured, stable, or progressive (Prog.) Alveolar Echinococcosis. PBMC 
from patients and controls were stimulated with E. multilocularis 
vesicle extract (EmV) for 24 (part a) and 48 hours (part b) or left 
unstimulated. Cytokine concentrations in cell culture supernatant were 
determined by specific ELISA. The EmAg-induced cytokine production 
(Netto Prod.) was calculated by subtracting the cytokine production in 
not stimulated PBMC cultures (baseline) from EmV-stimulated cytokine 
production (Brutto production). The cytokine production is shown as 
mean values in pg/mL with the 95% upper and lower confidence 
interval. The level of significance was adjusted by the Bonferroni-Holm 
method. The significant differences between groups are indicated (*P 
< 0.05, **P < 0.01, and ***P < 0.001). 
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4. Discussion 
Spontaneously healed Alveolar Echinococcosis has been 
observed [3], and previous works indicate that Th2-type 
immune responses in AE are associated with progressive 
AE while proinflammatory Th1-type cytokines are 
important in protection and disease regression. Therefore, 
we focused on pro-inflammatory cytokines of the IL-17 
family yet uncharacterized in AE and searched whether 
these immune mediators of inflammation and their 
receptors associated with progression or regression of AE. 
In the present study, pro-inflammatory IL-17 cytokine 
family members and their common receptors disclosed 
divergent cellular production profiles and plasma levels in 
AE patient groups and controls; Th17-type IL-17A levels 
were similar in patients with progressive, stable, and 
healed E. multilocularis metacestode lesions, IL-17B 
enhanced in AE patients, whilst the Th17-type IL-17F 
production was highest in controls and depressed in all 
AE patient groups. Such diverse and opposing cytokine 
profiles revealed distinct dynamics for each member of 
the IL-17 family during progression or regression of AE.  
While Th17 immune responses may confer protection 
against infections with bacteria and fungi [25, 26], they 
may also initiate inflammatory responses which promote 
immune disorders like inflammatory bowel disease and 
rheumatoid arthritis [17, 18]. The IL-17A and IL-17F 
cytokines are best characterized, highly homologous, and 
were initially allocated similar characteristics. Recent 
findings, however, disclosed that IL-17F is dispensable for 
immune disorders like collagen-induced arthritis and 
experimental autoimmune encephalitis, while effective 
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protection against Staphylococcus aureus and Citrobacter 
rodentium infections was dependent on the presence of 
both IL-17A and IL-17F activity [26]. IL-17F is rather 
associated with protection while IL-17A seems to 
contribute equally to both protection and inflammatory 
disorders [26, 27].  
In AE patients, irrespective of their stage of infection,  
IL-17F levels were depressed, and such cellular 
unresponsiveness and depressed cytokine production to 
E. multilocularis metacestode antigens have previously 
been observed [5, 6]. Furthermore, depressed IL-17F 
plasma and production levels persisted irrespective 
whether AE was cured, stable or progressive, suggesting 
continuing immune responses against residual parasite 
products. IL-17A and IL-17F are potent inducers of 
chemotaxis and inflammation, and both can be induced in 
PBMC by TGF-β, IL-6, and IL-21 secreted from antigen 
presenting cells (APC) [28, 29]. Both trigger 
proinflammatory responses by the release of neutrophil 
activating chemokine CXCL8/IL-8 [16] and of 
proinflammatory cytokines like TNF-α, IL-6 and IL-1β [30]. 
Suppression of Th17 immune responses has been 
demonstrated in infection models, where Fasciola 
hepatica-infected mice had a decreased production of IL-
17 [31] and Schistosoma mansoni-infected mice with an 
elevated IL-17 production presented with a reduced adult 
worm burden [32]. The IL-17 receptor family consists of 
five dimer-forming subunits (IL-17RA to IL-17RE). IL-17A 
and IL-17F share the same receptor subunit IL-17RA [27] 
and IL-17RA is expressed ubiquitously by all cell types 
[30]. Plasma concentrations as well as the E. 
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multilocularis antigen-induced cellular release of soluble 
IL-17RA were low in patients irrespective of their stage of 
AE and this paralleled the low plasma levels and the non-
inducible cellular release of IL-17A by PBMC from AE 
patients (data not shown). The observed lessened EmAg-
specific IL-17F and sIL-17RA levels in AE patients 
indicate a parasite-induced unresponsiveness occurring 
with active E. multilocularis infection and such cellular 
anergy may facilitate survival of the parasite in its host. 
Parasite antigen-specific cellular anergy was similarly 
observed in filariasis or schistosomiasis patients, where 
patent infection, that is, with circulating microfilariae in 
filariasis or egg excretion in schistosomiasis patient, 
associated with cellular hyporeactivity to parasite-specific 
antigens; often the patients’ cellular responses were lower 
than observed in endemic controls [33, 34].   
Up to date, little is known about the biological properties 
of IL-17B. Its expression has been found in the monocyte-
derived cell line THP-1, chondrocytes, and neurons [35–
37], and IL-17B mRNA was detected in cells of the 
gastrointestinal tract, including stomach, pancreas, and 
small intestine [35]. IL-17B signals through binding to a 
homodimeric IL-17RB complex and induces upon binding 
the release of proinflammatory TNF-α, IL-1β, and IL-6, 
CXCL8/IL-8 [36], and the migration of neutrophils to the 
peritoneal cavity in rats [38]. Protective properties of IL-
17B in disease have not yet been reported. In AE patients, 
plasma concentrations of IL- 17B and its soluble receptor 
IL-17RB were strongly elevated and highest in those with 
progressive AE. The persistent exposure to growing E. 
multilocularis metacestodes may have triggered the 
Publications 
103 
 
release of IL-17B by cells of the gastrointestinal tract, 
leading to the recruitment of neutrophil granulocytes into 
peri-parasite lesions. While the effects of IL-17B are 
similar to those mediated by TNF-α, IL-17A, and IL-1β, its 
potency is limited [39]. The IL-17B-induced infiltration of 
neutrophils into the peritoneal cavity in rats required much 
higher concentrations compared to TNF-α and it was still 
considerably less effective than the cell migration induced 
by IL-17A [38]. The elevated IL-17B production in AE 
patients disclosed a proinflammatory response triggered 
by E. multilocularis antigens, but potentially not strong 
enough to limit the progressive parasite growth. The 
decreasing concentration of IL-17B with an cured AE 
should be further evaluated as a prognostic marker in AE.  
IL-17RB serves as receptor subunit for IL-17B and IL-17E 
[40], commonly expressed by cells of the intestine, but 
also by liver, pancreas, lung, and kidneys as well as on 
Th2 and Th9 cells [27, 30, 40, 41]. Plasma concentrations 
of soluble IL-17RB were highly elevated in AE with no 
significant differences between the patient groups, while 
PBMC from progressive AE cases produced high 
amounts of soluble IL-17RB in response to E. 
multilocularis antigens. While vesicle extracts will contain 
large amount of vesicle fluid, the single-cell extract will 
most likely be derived from the inner germinal layer of the 
metacestode, and therefore, the heightened 
proinflammatory IL-17 responses in patients with 
progressive AE may primarily be induced by vesicle fluid 
components and germinal cells and engaging the  
IL-17RB activation pathway. Membrane bound and 
soluble IL-17RB are inducible in human antigen-
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presenting cells (APC) upon stimulation with Th2-type 
cytokines IL-4, IL- 10, IL-13 and TGF-β [42], and these 
cytokines are associated with progressive AE [5, 6, 8, 43, 
44]. PBMC from AE patients produced elevated levels of 
Th2 cytokines IL-4, IL- 5, and IL-10 upon stimulation with 
crude E. multilocularis antigen [5]. Thus, the cellular 
production of sIL-17RB in AE patients in response to E. 
multilocularis antigen could result from an EmAg-induced 
production of Th2 cytokines, which subsequently 
triggered the release of sIL-17RB. The higher 
concentrations of sIL-17RB in patients may be a direct 
consequence of this Th2 polarization associated with 
chronic AE. The biological functions and importance of 
soluble IL-17 receptors in AE remain tentative; the soluble 
IL-17RB could act as decoy receptor for IL-17B. Previous 
studies have shown that the administration of the soluble 
IL-4 receptor inhibited IL-4-mediated immune responses 
[45], while soluble IL-6 receptor amplified the effects of IL- 
6 [46]. High amounts of circulating IL-17RB, as observed 
with progressive AE, could counteract the effects of IL-
17B, thus silencing IL-17B-mediated pro-inflammatory 
responses in patients. Similar to IL-17F, the high amounts 
of soluble IL-17RB observed in plasma of patients with 
cured AE might indicate long-lasting effects of residual or 
inactive parasite lesions, whilst low levels of circulating 
soluble IL- 17RA together with low IL-17F production may 
reduce Th17 cytokine-mediated inflammation.  
 
5. Conclusion 
In summary, the present work discloses a modulation of 
proinflammatory IL-17 family members and Th17-type 
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immune responses in AE; the persistently altered 
production of IL-17 cytokine family members and of their 
soluble receptors highlights the capacity of the E. 
multilocularis metacestode to exert long-lasting immune 
modulating effects, and further studies should address the 
protective and preventive potential of IL-17 cytokines 
during E. multilocularis infection. 
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Abstract 
Metacestode larvae of the tapeworm Echinococcus 
multilocularis can cause alveolar echinococcosis (AE), a 
severe parasitic disease in man, which, if it remains 
untreated, may cause organ failure and death. 
Spontaneous and parasite antigen-induced cellular 
responses were studied in patients with cured, stable and 
progressive AE to differentiate the response profiles 
between the distinct states of infection. Antibody reactivity 
was evaluated in AE patients with cured, stable, and 
progressive disease. The spontaneous cellular release of 
pro-inflammatory IL-31, IL-33 was clearly depressed in all 
AE patients, while regulatory IL-27, anti-inflammatory 
SDF-1/CXCL12 and eosinophil granulocyte attracting 
Eotaxin-1, -2 and -3 (CCL11, CCL24, CCL26) were 
enhanced with disease progression. Such distinctive 
response profiles could be applied for monitoring of AE 
disease progression or regression. E. multilocularis 
metacestode (Em) antigens (entire metacestode EmAg as 
well as EmVesicles) stimulated in vitro IL-31, IL-33, 
Eotaxin-1, -3 and CXCL12 cytokine and chemokine 
responses, which were similarly present in all AE patient 
groups, while regulatory IL-27 were suppressed and pro-
inflammatory Eotaxin-2 was enhanced. E. multilocularis 
metacestode-specific IgG1, IgG3 and IgE responses 
progressively diminished with regression from active to 
stable and cured AE. IgG2 and IgG4 reactivity remained 
similarly high in stable and progressive cases, and 
lessened only with cured AE. Antibody reactivity against 
E. multilocularis vesicle antigen distinctively separated 
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between cured, stable or progressive AE, with the 
exception of IgG4.  
In sum, the combined and longitudinal study of several 
cytokines and chemokines, together with the evaluation of 
E. multilocularis vesicle-specific antibody responses, 
should provide a better understanding of the immune 
response during progression and regression of AE, and 
may help to improve the staging of AE patients. 
 
Keywords Echinococcus multilocularis; Cytokines; 
Chemokines; Antibody; Staging 
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Introduction 
For the tapeworm Echinococcus multilocularis, the 
definitive hosts are mainly foxes and dogs, and rarely 
man also can become infected  by accidentally ingesting 
E. multilocularis eggs [1]. In the human host, the egg-
hatched cestode larvae (metacestode) will predominantly 
develop in the liver, may proliferate and cause tissue 
damage and ultimately organ failure. The metacestode 
can also spread to secondary organs by infiltrative growth 
or metastatic dissemination. Humans infected with E. 
multilocularis may remain asymptomatic without evident 
parasite growth for decades, and yet the infection may 
subsequently progress into a chronic or progressive state. 
Indeed, the number of established infections was found to 
be far lower than the estimated number of exposures [2,3] 
- only 1 out of 10 subjects serologically positive for E. 
multilocularis will grow metacestode larvae and develop 
AE [1].  Evidence points to a host-parasite interplay and 
modulation of the host immune responses as decisive 
determinants permitting progressive parasite growth and 
host tissue infiltration. Progression to severe AE may be 
very slow and the infection is often detected incidentally 
by imaging techniques [4], but late diagnosis of clinical 
manifestations without adequate treatment may result in 
case fatality. Thus, early detection of viable and 
proliferating metacestodes and appropriate intervention 
will lead to a better prognosis.  
Detection of helminth-specific immunoglobulins is highly 
sensitive and specific using affinity-purified and 
recombinant antigens [5-7]. IgG1, IgG2, IgG4 and IgE 
were found to be highly reactive in cystic echinococcosis 
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(CE) and in AE patients, which may indicate active E. 
multilocularis infestation and severe outcome of disease 
[8]. The combined use of ELISA and Western Blot assays 
has been recommended for the differential diagnosis of 
human echinococcosis [9,10]. Furthermore, predominant 
Th2-type cellular immune responses together with high 
levels of IgG4 and IgE were associated with progressive 
and severe AE [8].    
Cellular effector responses appear crucial for prevention 
of E. multilocularis metacestode growth and 
dissemination as well as for protection of the host against 
parasite-induced inflammation and tissue damage [11]. 
Th2-type cytokines IL-4, IL-10 and Th1-type interferon-
gamma (IFN-γ) and the chemokine MDC/CCL22 were 
produced by PBMC from AE patient in response to EmAg 
[12-14]. Besides, immune-modulating properties of E. 
multilocularis on Th17 cytokine-mediated pro-
inflammatory immune responses were observed in AE 
patients [15], which may facilitate the tissue-infiltrative 
growth of the parasite and its persistence in the human 
host. Eotaxin-1, -2 and -3 (CCL11, CCL24 and CCL26) 
are involved in the recruitment of eosinophils, mast cells 
and Th2 lymphocytes [16] and CCL11 and CCL24 were 
proved to be pivotal in the immune response against 
Schistosoma mansoni infection [17]. Regulatory cytokines 
IL-27 can induce a strong proliferation of naive human B 
cells, CD4+ and CD8+ T-cells and will promote the 
development of Th1 cells [18-20]. The pro-inflammatory 
IL-31 and IL-33 are Th2-type cytokines and are 
suggested to play a vital role in human T-cell mediated 
skin diseases and allergic and non-allergic diseases 
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[21,22]. IL-33 will activate Th2-type helper cells, mast 
cells and basophil granulocytes, thus supporting host 
defense against nematodes [23,24].  
In the present study, we analyzed the parasite antigen-
specific cytokine, chemokine and antibody responses in 
patients with cured, stable and progressive AE, and in 
infection-free controls. Dynamic profiles of the humoral 
and cellular immune responses were observed during 
disease progression and regression, and these 
observations may help to improve monitoring and staging 
of AE.  
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Materials and Methods 
Study participants 
All alveolar echinococcosis patients were admitted for 
consultations at the Echinococcosis Reference Center 
(University Hospitals of Ulm; 38 females/29 males, mean 
age was 55 years). The Echinococcosis Center in Ulm 
and University Hospitals of Tübingen are located in south 
west of the federal state of Baden-Wüttemberg in 
Germany, both towns being 70 km apart, in an endemic 
area for E. multilocularis. It was estimated that about 61 
cases of AE will be detected annually in Germany [25]. 
The AE patients in the present study were classified into 
cured, stable and progressive according to WHO-PNM 
criteria which were established by the WHO Informal 
Working Group on Echinococcosis [26]. Diagnosis and 
classification of AE was performed using positive imaging, 
serology and histology according to the WHO-PNM 
system (P = parasitic mass in the liver, N = involvement of 
neighboring organs, and M = metastasis) [26], and most 
patients were re-examined regularly during follow-up. 
Echinococcosis patients were diagnosed and grouped as 
cured (n=10), stable (n=36) and progressive (n=21) AE. 
All healthy controls (n=10) were blood donors at 
University Hospitals of Tübingen; all controls were 
negative in E. multilocularis antigen-specific antibody 
ELISA responses which confirmed their infection-free 
state. All patients gave their written consent to participate 
in this study, and approval for the latter was obtained from 
the ethical board of the University Clinics of Ulm (Ethik-
Kommision Antragsnummer 71/2004). 
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In vitro culture of E. multilocularis metacestode 
The E. multilocularis metacestode was collected from an 
infected AE patient in Germany, and thus belonging to the 
E.multilocularis Europe strain. E. multilocularis 
metacestodes was cultured in vitro as previously 
described [27,28]. Briefly, metacestode tissues were 
removed aseptically from the peritoneal cavity of infected 
Meriones unguiculatus and cut into small tissue blocks. 
These tissues were cultivated using complete RPMI 1640 
medium (5% FCS and 1% antibiotic and antimycotic 
solution) in an incubator (37 ℃, saturated humidity, and 5% 
CO2). After several weeks, metacestodes start to 
proliferate and produce daughter vesicles. The culture 
medium was renewed weekly and viable E. multilocularis 
metacestode vesicles were collected for E. multilocularis 
vesicle antigen (EmVAg) preparation.  
 
Preparation of E. multilocularis antigens 
EmAg and EmVAg were prepared as previously 
described [29,30]. For EmVAg preparation, E. 
multilocularis vesicles were homogenized and sonicated 
(30% intensity, pulse 1s for 8 min) on ice. The vesicle 
homogenate was then centrifuged at 5000g for 30 min at 
4 ℃, the supernatant was collected after sterile-filtration 
(0.22μm) as EmVAg and stored at -80 ℃. For EmAg 
preparation, solid metacestode tissues were ground on 
ice in a Ten-Broek tissue grinder until a homogenous 
liquid extract emerged; the liquid extract was then 
collected and centrifuged at 15,000g for 30 min at 4 ℃. 
The supernatant was sterile-filtered (0.22μm) and stored 
at -80℃ as EmAg. The protein concentration of these E. 
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multilocularis antigens was determined using the 
bicinchoninic acid protein determination kit (Pierece, 
Rockford, IL, USA). 
 
Isolation and activation of peripheral blood 
mononuclear cells 
Whole blood samples from AE patients were processed at 
the blood transfusion center at the University Hospitals of 
Ulm. Buffy-coated cells of healthy controls were 
processed at the blood transfusion center at the 
University Hospital of Tübingen. PBMC and plasma from 
AE patients and healthy controls were isolated by Ficoll-
Paque (Pharmacia, Freiburg, Germany) density gradient 
centrifugation as described previously [31]. From every 
AE patient serum was collected and stored at -80℃. 
PBMC were cultured and stimulated as described 
previously [31]. Briefly, PBMC were adjusted to 
1x107cells/ml using complete RPMI 1640 medium (10% 
FCS and 1% antibiotic and antimycotic solution) and 
plated 500μl/well onto 48-well flat-bottomed tissue culture 
plates. Then, the PBMC were cultured for 48h at 37℃, 
saturated humidity and 5% CO2 in the presence of 50μl 
EmVAg (final concentration 60ug/ml) or 50μl EmAg (final 
concentration 60ug/ml) or remained un-stimulated as a 
control (baseline). PBMC were cultured as a control 
(baseline). Cell culture supernatant was collected and 
separated by centrifugation, and stored in -80℃. 
 
Evaluation of E. multilocularis-specific IgG subclass 
and IgE responses in AE patients 
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To evaluate parasite-specific serological reactivity, the 
levels of IgG subclasses (IgG1, IgG2, IgG3 and IgG4) and 
IgE in AE patients sera against EmAg or EmVAg were 
quantiﬁed by enzyme-linked immunosorbent assay 
(ELISA) as previously described [8,29]. Brieﬂy, microtitre 
plates (Maxisorb, Nunc, Denmark) were coated with 
EmAg or EmVAg (5μg/ml); nonspeciﬁc binding capacity of 
wells was blocked by PBST-BSA (PBS with 0.05% Tween 
20, 5% Bovine serum albumin), then washed with 
washing buffer before application of AE patient sera (1:8 
diluted). Total IgE and IgG subclasses were detected with 
HRP-conjugated mouse anti human IgG subclasses or 
IgE antibodies (1:1000, Invitrogen, CA, USA) and the 
optical densities were then measured at 450 nm using a 
microplate autoreader (EL808, BioTek instrument Inc., VT, 
USA). 
 
Determination of cytokine and chemokine production 
by PBMC and plasma 
PBMC culture supernatants were collected for further 
analysis after 48h of stimulation with EmAg or EmVAg. 
From every patient serum and plasma samples were 
collected. Cytokines and chemokines secretion was 
quantified using sandwich ELISA kits for IL-27, IL-31, IL-
33, CCL11, CCL24, CCL26 and CXCL12 (R&D Systems, 
Minneapolis, MN, USA). The measurement was 
performed according to the guidelines of the 
manufacturers. Optical densities (OD) were transformed 
into concentrations (pg/ml) according to the 
cytokine/chemokine-specific standard curve. 
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Data analysis and statistics 
The statistical package JMP10 was used to compile 
statistical analyses. Significant differences of cytokines, 
chemokines levels and immunoglobulin responses were 
determined using Tukey’s test (with Bonferroni correction). 
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Results 
E. multilocularis antigen-induced cytokine (IL-27, IL-
31 and IL-33) production in AE patients and infection-
free controls 
The cellular production of regulatory IL-27, pro-
inflammatory IL-31 and IL-33 by PBMC in vitro are shown 
in Figure 1. The spontaneous release of IL-31 and IL-33 
was low in AE patients, while IL-27 levels were elevated. 
Different baseline levels of IL-27, IL-31 and IL-33 
corresponded with the states of infection in AE patients; 
IL-31 and IL-33 were low in AE patients at all states of 
infection and highest in infection-free controls. In contrast, 
regulatory cytokine IL-27 was spontaneously released 
highest by PBMC in increasing amounts as AE 
progressed with severity. Such distinctive response 
profiles could be applied for monitoring progression or 
regression of AE disease. After PBMC were co-cultured 
with EmAg or EmVAg, a low production of IL-27 and IL-33 
in AE patients was observed, but significantly higher 
amounts of IL-33 were observed in controls when 
compared with AE patients. The production of IL-31 in AE 
patients was inducible by EmAg and EmVAg above 
baseline, but IL-31 levels were similar in AE patients and 
controls. Cytokine IL-27 and IL-33 production was not 
inducible by EmAg or EmVAg. The plasma levels of IL-27, 
IL-31 and IL-33 were low in AE patients, and similar 
amounts were found in progressive, stable and cured AE 
patients (data not shown). 
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Fig.1  
Spontaneous and E. multilocularis antigen-induced cellular production 
of IL-27, IL-31 and IL-33 alveolar echinococcosis (AE) patients and 
infection-free controls (n=10).  AE patients were grouped according to 
their state of E. multilocularis infection, i.e. cured (n=12), stable (n=36) 
or progressive (n=21). Peripheral blood mononuclear cells (PBMC) 
were co-cultured for 48h with either E. multilocularis vesicle antigen 
(EmVAg: 60 g/ml) or E. multilocularis metacestode antigen (EmAg: 
60 g/ml). Cytokine concentrations in cell-free culture supernatants 
were determined by cytokine-specific ELISA and are shown as 
baseline (spontaneous cytokine release without addition of EmVAg or 
EmAg) and brutto production (cytokine release induced by antigen 
without subtraction of the baseline spontaneous release). Production 
values between the groups were analyzed using Tukey’s test and 
significant differences are indicated. (* p < 0.05; ** p < 0.01) 
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E. multilocularis antigen-induced chemokine 
(Eotaxin-1/CCL11, Eotaxin-2/CCL24, Eotaxin-3/CCL26 
and SDF-1/CXCL12) production in AE patients and 
infection-free controls 
 
The in vitro production by PBMC of CC-chemokines 
eotaxin-1, eotaxin-2 and eotaxin -3 (CCL11, CCL24 and 
CCL26) and of CXC-chemokine CXCL12 are shown in 
Figure 2. Spontaneous (baseline) release of CCL11, 
CCL24, CCL26 and CXCL-12 was highest in patients with 
progressive AE. Baseline levels of Eotaxin 1, -2 and -3 
decreased as AE regressed from progressive to stable 
and cured infection.  When PBMC from AE patients were 
stimulated with EmAg and EmVAg, production of CCL11 
was enhanced in all AE patient groups to similar levels. E. 
multilocularis vesicle antigen (EmVAg) activated CCL26 
production in cured and progressive AE patients, while 
EmVAg strongly stimulated CXCL12 release only in 
PBMC from progressive AE patients. The plasma levels 
of CCL11, CCL26 and CXCL12 did not differ between the 
study groups (data not shown). 
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Fig.2   
Spontaneous and E. multilocularis antigen-induced cellular production 
of Eotaxin-1/CCL11, Eotaxin-2/CCL24, Eotaxin-3/CCL26 and SDF-
1/CXCL12 alveolar echinococcosis (AE) patients and infection-free 
controls (n=6). AE patients were grouped according to their state of E. 
multilocularis infection, i.e. cured (n=10), stable (n=10) or progressive 
(n=6). Peripheral blood mononuclear cells (PBMC) were co-cultured 
with either E. multilocularis vesicle antigen (EmVAg: 60 ug/ml) or E. 
multilocularis entire metacestode antigen extract (EmAg: 60 ug/ml) for 
48h. Cytokine concentrations in cell-free culture supernatants were 
determined by cytokine-specific ELISA and are shown as baseline 
(spontaneous cytokine release without addition of EmVAg or EmAg) 
and brutto production (cytokine release induced by antigen without 
subtraction of the baseline spontaneous release). Production values 
between the groups were analyzed using Tukey’s test, and significant 
differences are indicated. (* p < 0.05) 
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E. multilocularis antigen-specific antibody responses 
in AE patients and infection-free controls 
 
In AE patients and controls, antibody isotype responses 
to E. multilocularis metacestode (EmAg) and to E. 
multilocularis vesicle antigen extract (EmVAg) were 
quantified by ELISA; the results are shown in Figure 3 a, 
b and c. IgG1, IgG2, IgG3 and IgG4 responses to EmAg 
and EmVAg increased with disease progression, the 
highest reactivity being observed in patients with 
progressive AE. IgG2 and IgG4 responses were similarly 
high in patients with stable and progressive AE. Lowest 
IgG subclass responses were present in cured AE 
patients and controls. Parasite antigen-specific IgE 
reactivity was highest in patients with progressive AE, and 
IgE responses were at similar levels with cured and stable 
AE. Thus, apart from the entire EmAg metacestode 
antigen extract, the E. multilocularis vesicle antigen 
appeared valuable for serological detection of 
echinococcosis and differentiation between the distinct 
states of AE. 
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Fig.3  
Serum samples were collected from alveolar echinococcosis (AE) 
patients (cured, n=21; stable, n=21; progressive, n=6) and infection-
free controls (n=10). Antibody IgG1, IgG2, IgG3 and IgG4 subclasses 
reactivity to E. multilocularis entire metacestode antigen extract (EmAg; 
Panel a) and to E. multilocularis vesicle antigen (EmVAg; Panel b) was 
determined by ELISA. Panel c) shows IgE responses to EmAg and 
EmVAg. Statistical differences between patient groups and controls 
were analyzed using Tukey’s test, and significant differences are 
indicated. (*p<0.05; ** p < 0.01; *** p < 0.001) 
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Discussion  
Cytokines and chemokines link innate and adaptive 
immunity [32]; they can act as central contributors to 
severe and life-threatening illness and are also an 
important regulatory element against inflammatory 
diseases. During the course of AE, both regulatory and 
inflammatory cytokines and chemokines levels will 
change in AE patients, so cytokine profiling at distinct 
states of AE may help not only to better understand host-
parasite interactions but to reveal whether the disease is 
progressive, stable or cured. In the present cohort three 
times as much stable, twice as much progressive, than 
cured AE patients were studied; such imbalance of 
patients groups is reflecting the course of AE where 
progressive disease may become stabilized by clinical 
intervention in most patients. However, the regression 
from stable disease to cure is difficult to achieve, often 
due to multiple metacestode lesions, re-activation of 
parasite growth, unresponsiveness to treatment and 
metacestode lesions inaccessible for surgery.  
To our best knowledge, the quantification of IL-27, IL-31 
and IL-33 and the Eotaxins -1, -2 and -3 has not been 
investigated in AE yet. The observed response profiles 
with cured, stable and progressive AE suggests them as 
useful makers for disease monitoring. Furthermore, the 
application of proliferating and tissue invading 
E.multilocularis vesicles as antigen to dissect between 
disease stages has the potential to refine AE serological 
diagnosis and patients monitoring. Here, our work 
presents new findings which show that by combined 
monitoring of cytokines (IL-27, IL-31 and IL-33) together 
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with eotaxin -1, -2, -3 chemokines and antibody subclass 
responses to proliferating vesicles of E. multilocularis may 
offer an approach for distinctive staging of AE.  
Spontaneous but not antigen-driven release of IL-27 
increased with disease severity in AE patients, suggesting 
the presence of immune regulatory mechanisms which 
may dampen inflammation induced by persistent E. 
multilocularis. The biphasic cytokine IL-27 first potentiates 
Th1-type responses and inflammatory signals generated 
during the early phase of infection; thereafter, with 
persistent pathogen exposure and chronic infection, IL-27 
inhibits both pro-inflammatory Th2 and Th17 cytokine 
releases [33]. Enhanced spontaneous release of IL-27 in 
AE patients with stable and progressive disease thus 
indicates the emergence of a regulatory component 
depressing pro-inflammatory cytokine and chemokine 
responses; such regulatory IL-27 production are likely to 
be induced by viable and persistent E. multilocularis 
metacestodes in AE patients.  
In contrast, spontaneous production of cytokines IL-31 
and IL-33 were found to be lowest in AE patients with 
progressive disease. Preferentially produced by Th2-type 
helper cells, IL-31 is a potent inducer of pro-inflammatory 
effects in monocytes and macrophages [34,35], and the 
“alarmin” IL-33 is associated with cellular damage and 
Th2-type inflammatory disease pathogenesis [36]. High 
expression of IL-33 was observed in unbalanced Th1/Th2 
immunity biased parasite infections, such as visceral 
leishmaniasis [37], toxoplasmosis [38] and severe malaria 
[39]. Multi-cellular parasites like E. multilocularis may 
escape elimination from their host by interfering with 
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immune defense mechanisms, while the secretion of 
immune modulators by E. multilocularis inhibits T cells 
and diverts the activation of monocytes and macrophages. 
Several studies have shown that metacestodes of 
E.multilocularis release factors which impair the 
interaction of macrophages and T-cells in mitogen- and 
antigen-induced lymphoproliferative responses [40,41]. 
Futher, E. multilocularis protoscoleces can modify the 
proliferation of murine T and B cells, and alter the 
cytokine secretion in macrophages/monocytes [42]. By 
depressing Th1-type IFN-γ and inflammatory MIP1α while 
activating immune regulatory TARC/CCL17 and RANTES 
[14,30], E. multilocularis reduces inflammatory responses, 
prevents tissue destruction and organ damage, and 
facilitates parasite persistence within its host. Observed 
low levels of inflammation-associated IL-31 and IL-33 with 
chronic AE support the notion that with parasite 
persistence, equilibrated levels of pro-inflammatory and 
regulatory cytokines and chemokines may have evolved 
to prevent disease progression and, at the same time, 
protect the host against immune-effecter cells mediated 
damage.  
Both regulatory and pro-inflammatory cytokines and 
chemokines were generated by PBMC from AE patients 
after activation with E. multilocularis metacestode 
antigens. Previous studies have shown that Th1-type 
cellular response efficiently kill E. multilocularis 
metacestodes and control echinococcosis [11,43], 
whereas with disease progression Th2 responses prevail 
[44-46]. Prominent IL-5 expression by CD4+ T 
lymphocytes was induced in AE patients [47], activating 
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eosinophil granulocytes; in the present investigation, we 
observed enhanced spontaneous releases of eotaxins in 
all AE patient groups. With inflammation and immune 
activation, eotaxins attract eosinophil granulocytes to 
inflamed tissues; our findings signify that such cellular 
effecter responses are induced by vital metacestode 
tissues, and still remain active in patients staged with 
cured AE. This indicates that not only viable and 
proliferating metacestodes of E. multilocularis, but 
residual parasite lesions as well modulate cellular 
immune responses in AE patients. Similarly, elevated 
CCL11 and CCL24 levels were observed in human 
neurocysticercosis and human angiostrongyliasis [48,49], 
and eosinophil-mediated defense mechanism against 
helminthes was of paramount importance [50]; however, 
eotaxins and eosinophil accumulations were also 
suggested as having a disease-promoting role in atopic 
dermatitis and bronchial asthma [16,51]. The CXC 
chemokine CXCL12/SDF-1 was strongly expressed in 
lung and liver metastases [52], recruiting leukocytes into 
infected tissues and promote inflammation [53]. An up-
regulated production of CXCL12 was found in rheumatoid 
arthritis, nephritis and asthma [54-56]. The spontaneous 
release of CXCL12 was highest in patients with 
progressive AE, indicating that CXCL12 participates in the 
inflammatory progress with active AE.  
Distinctive antibody responses are known to correlate 
with the clinical state of helminthes infections, with IgG4 
and IgE indicative of a Th2-type immune response and 
prominent in chronic helminthes infections [5,7,57]. In 
cystic echinococcosis, a prevalent IgG4 response was 
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associated with cystic growth and disease progression 
[58], while IgG1 and IgG4 subclasses were dominant for 
AE in man [59].  
In the present investigation, E. multilocularis 
metacestode-specific IgG1, IgG3 and IgE responses 
progressively diminished with regression from active to 
stable and cured AE, while IgG2 and IgG4 reactivity 
remained similarly high in stable and progressive cases, 
and diminished only in cured AE. As previously shown, 
IgE responses decrease rapidly in cystic echinococcosis 
and in AE patients following surgery or successful 
chemotherapy [60,61]; it was similarly observed in this 
study that specific IgE levels against EmAg dramatically 
decreased in cured AE patients. Several studies have 
also shown that increased IgE correlated with progressive 
AE [8,62,63]; similarly, in this study, patients with 
progressive AE had the highest IgE reactivity. The 
EmVAg specific antibodies performed best in 
distinguishing between cured, stable or progressive AE; 
here antibody subclasses reactivity, with the exception of 
IgG4, differentiated clearly between progressive and 
stable AE.  
In sum, combined and longitudinal study of several 
cytokine and chemokines, in combination with evaluation 
of E. multilocularis vesicle-specific antibody responses, 
should provide a better understanding of the immune 
response during progression and regression of AE, and it 
may help to improve the staging of AE patients. 
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